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Abstract 
This thesis tested whether cognitive performance during passive heat stress may be 
affected by changes in cerebrovascular variables as opposed to strictly thermally-induced 
changes. A pharmacological reduction in cerebral blood flow (CBF) using indomethacin 
along with a hypocapnia-induced CBF reduction during passive heat stress (Tre ~1.5°C 
above baseline) were used to investigate any cerebrovascular-mediated changes in 
cognitive performance. Repeated measures analysis of variance indicated that One-Touch 
Stockings of Cambridge (OTS) performance was not affected by a significant reduction 
in CBF during passive heat stress. More specifically, OTS accuracy measures did not 
change as a result of either a reduction in CBF or increasing passive heat stress. However, 
it was found that OTS response time indices improved with increasing passive heat stress 
independent of CBF changes. In conclusion, a significant reduction in CBF does not 
cause additional changes in performance of an executive functioning task during severe 
passive heat stress. 
Key Words: heat stress, executive function, cognitive performance, cerebral blood 
flow. 
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1 Introduction 
The physiological effects of heat stress and hyperthermia on cognitive function 
have been well documented throughout history (Hancock et al., 2007; Pilcher et al., 
2002). However, definitive conclusions regarding these effects remain inconsistent and 
contradictory. The differences in findings have been generally attributed to the 
conflicting nature of previous research methods. As outlined by Gaoua (2010), these 
inconsistencies can range from differences in task complexity and task type used in 
assessing cognitive function, the technique used to induce hyperthermia, and the overall 
intensity and duration of thermal stress test conditions.  
Changes in cognitive function during hyperthermia can occur as a result of 
variations in skin and core temperature (Gaoua et al., 2012; Hancock & Vasmatzidis, 
2003; Simmons et al., 2008). For example, with immediate and short duration heat 
exposure, rapid increases in skin temperature results in a feeling of unpleasantness, 
otherwise known as the alliesthesial effect (Cabanac, 1971). This disrupts the homeostatic 
balance within the body, causing additional attentional demands and competition for 
neuronal resources that impairs the successful completion of a concurrent complex 
cognitive task (Gaoua et al., 2012). Moreover, prolonged heat exposure causes a 
significant increase in core temperature above which can be adequately compensated by 
the body’s homeostatic mechanisms (e.g. heat loss pathways). It has been proposed that 
increased attentional resource demand/depletion (Hancock, 1989; Hancock & 
Vasmatzidis, 2003) and/or limited conscious access to attentional resources (Baars, 1993) 
are the principal sources of cognitive failure during heat stress. With regards to short 
duration heat exposure (<30 min; eliciting acute changes in skin temperature without 
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concomitant rise in core temperature), it is widely accepted that cognitive decrements are 
caused by variations in skin temperature causing increased resource demands/depletion 
(Gaoua et al., 2012; Hancock & Vasmatzidis, 2003; Pilcher et al., 2002; Ramsey & 
Kwon, 1992). However, definitive conclusions regarding the potential mechanisms of 
cognitive decline during prolonged heat stress (> 30 min; eliciting significant changes in 
skin and core temperature) are more difficult to elucidate due to the numerous disruptions 
in physiological homeostasis that occur under these conditions.  
In addition to the aforementioned concepts regarding cognitive decline during 
prolonged hyperthermia, recent findings have yielded another potential physiological 
hypothesis. One indirect result of heat stress is a hyperthermia-induced hyperventilation, 
which reduces arterial partial pressures of carbon dioxide (PaCO2) (Haldane, 1905). Kety 
& Schmidt (1948) first showed that the cerebral vasculature is highly sensitive to changes 
in PaCO2 such that hypocapnia will result in cerebral vasoconstriction and a subsequent 
decline in cerebral blood flow (CBF). It is possible that during prolonged, intense heat 
exposure, PaCO2 will be sufficiently reduced to instigate a significant decline in CBF and 
hence cerebral oxygen delivery (Brothers et al., 2009; Nybo et al., 2014). Therefore, it 
can be postulated that these aforementioned physiological disturbances in homeostasis 
accompanying hyperthermia may have a direct effect on concurrent cognitive processing. 
Unfortunately, current research has been unable to adequately discern the effect of 
specific cerebrovascular factors occurring with hyperthermia. 
Therefore, to examine the potential role of changes in the cerebrovasculature on 
cognitive impairment with hyperthermia, the present experiment independently altered 
end-tidal carbon dioxide (PETCO2; a surrogate for PaCO2) and CBF during passive heat 
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stress. Using a pharmacological intervention (indomethacin), it is possible to manipulate 
CBF and oxygen delivery without concomitant changes in other physiological variables. 
In addition, via the use of end-tidal forcing, PETCO2 can be clamped at baseline 
(isocapnia) to prevent the natural decline in PETCO2 with heat stress-induced 
hyperventilation. Through these methods, it is theoretically possible to partition what 
physiological perturbation is the most likely contributor to reduced cognitive 
performance during prolonged heat stress. Therefore, the purpose of the present study 
was to examine cognitive performance of individuals completing an executive 
functioning task during passive heat stress with and without concomitant changes in 
PETCO2 and CBF. 
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2 Review of Literature 
2.1 Hyperthermia  
The ability to prolong exposure duration and uphold consistent performance levels 
requires equilibrium between heat production and heat dissipation (Casa, 1999). 
Hyperthermia is defined by the International Union of Physiological Sciences - Thermal 
Commission (Commission, 2001) as, “the condition of a temperature regulator when core 
temperature is above its range specified for the normal active state of the species” (p. 
257). During exposure to high environmental temperatures and humidity levels, the body 
relies on conduction, convection, evaporation, and radiation as heat exchange pathways.  
Ultimately, heat production must be matched by any combination of the four heat-
loss pathways to maintain thermal homeostasis and is characterized by the heat balance 
equation. This can be expressed as: 
?̇? =  ?̇? ±  𝑊𝑘̇ ±  ?̇? ±  ?̇? ± ?̇? − ?̇? 
Where ?̇? is body heat storage, 𝑀 ̇ is metabolic heat production, 𝑊𝑘̇  is mechanical 
work, and ?̇?, ?̇?, ?̇?, and ?̇? represent radiation, conduction, convection and evaporation, 
respectively. When it comes to high environmental temperature exposure, ?̇?  will 
represent a positive value, or a gain in heat storage (Cheung, 2009). If this increase in 
heat storage cannot be mitigated through heat loss mechanisms, it will eventually lead to 
a state of hyperthermia within the body.  
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2.1.1  Hyperthermia and Cerebrovascular Dynamics 
Hyperthermia has been shown to elicit dramatic changes in ventilation such that 
during prolonged heat stress there is an increased hyperventilatory response, or thermal 
hyperventilation. As first noted by Haldane (1905), hyperthermia elicits a pronounced 
increase in respiratory frequency and tidal volume. In turn, this thermal hyperventilation 
reduces arterial partial pressures of carbon dioxide (PaCO2), with an increase of ~1.5-
2.0°C in core temperature reducing end-tidal partial pressures of carbon dioxide levels 
(PETCO2) – a validated measure of PaCO2 during hyperthermia (Brothers et al., 2011) – 
by ~5-15 mmHg (Bain et al., 2014). However, an increase in core temperature of ~1.0°C 
must be elicited prior to observing any noticeable hyperventilatory response (Barltrop, 
1954). 
The resultant decrease in PaCO2 with hyperthermia also alters cerebral blood flow 
(CBF) and hence cerebral oxygen delivery (𝐶𝐷𝑂2), which is a product of CBF and arterial 
oxygen content (𝐶𝑎𝑂2)(Amann & Calbet, 2008). PaCO2 is widely regarded as one of the 
most influential factors in CBF regulation at both rest and exercise (Ide & Secher, 2000; 
Kety & Schmidt, 1948; Querido & Sheel, 2007; Willie et al., 2014). This phenomenon, 
termed “cerebrovascular CO2 reactivity”, is an index that describes the ability of the 
cerebrovascular arterioles to dilate or constrict relative to changes in PaCO2 (Ogoh & 
Ainslie, 2009). During hypocapnia (a physiological state of decreased PaCO2), the 
cerebral vasculature will vasoconstrict, subsequently reducing CBF. This mechanism is 
proposed to explain the attenuation of CO2 washout from the brain in an attempt to 
maintain/increase PaCO2 levels (Ainslie & Duffin, 2009; Ogoh & Ainslie, 2009). 
Conversely, hypercapnia (a state of increased PaCO2) causes cerebral vasodilation thus 
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increasing CBF. This increase in CBF is suggested to aid in the washout of CO2 from the 
brain and limits any further elevation in central PaCO2 (Ainslie & Duffin, 2009; Ogoh & 
Ainslie, 2009). Ainslie & Duffin (2009) has calculated that average global CBF reactivity 
is ~3.8%/mmHg change in PaCO2 within the eucapnic range of 35-55 mmHg. This 
cerebrovascular CO2 reactivity is generally higher in the hypercapnic range (~3-6% 
increase in CBF/mmHg) as opposed to the hypocapnic range (~1-3% decrease in 
CBF/mmHg) (Ide et al., 2003; Sato et al., 2012; Willie et al., 2012; Willie et al., 2014). 
As a result of these cerebrovascular changes in response to hyperthermia, CBF, 
indicated by a change in middle cerebral artery velocity (MCAv), has been shown to 
decrease throughout a range of core temperatures. Fan et al. (2008) showed that with 
increasing core temperature, there is a concomitant reduction in CBF (+0.5°C = -6%; 
+1.0°C = -13%; +1.5°C = -23%; +2.0°C = -32%). These results are in agreement with 
numerous other studies (Brothers et al., 2009; Low et al., 2008; Nelson et al., 2011; Ogoh 
et al., 2013) that have found similar decrements in MCAv with varying levels of 
hyperthermia. 
Recently, it has also been suggested that hyperthermia may elicit reductions in CBF 
as a thermoregulatory response in an attempt to dissipate heat from the head, termed the 
thermoregulatory steal theory (Hasegawa & Cheung, 2013). In a study by Sato et al. 
(2011), it was found that moderate hyperthermia led to a reduction in MCAv, by way of 
the internal carotid artery (ICA). Simultaneously, there was a rise in external carotid 
artery (ECA) flow, which feeds the blood vessels of the face and neck region. 
Unfortunately, because Sato et al. (2011) did not take any thermal measurements (core or 
skin temperature), it is difficult to confirm whether or not there is a correlation between 
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cerebral blood flow diversion and hyperthermia. In response to this, Bain et al. (2013) 
investigated whether there is a blood stealing mechanism by the ECA for 
thermoregulatory purposes during hyperthermia. Despite a 2.0°C increase in core 
temperature, it was found that there was no relationship between the large increases 
observed in the ECA (~250%) and the decreases in the ICA (Bain et al., 2013). These 
results all but refute the thermoregulatory steal theory; however, it does confirm that 
there is an increase in ECA blood flow with hyperthermia. This also confirms that despite 
decreases in other cerebral arteries with hyperthermia-induced hypocapnia, the ECA 
blood flow is remarkably well preserved (even increased), most likely for the purpose of 
heat dissipation. 
In addition to the aforementioned physiological responses to hyperthermia, there is 
a likely increase in cerebral metabolic rate (CMRO2) (Bain et al., 2014; South, 1958). As 
previously noted, with hyperthermia, there is a concomitant decline in CBF. A result of 
this change in CBF is a reduction in oxygen (O2) delivery, which is ultimately 
counteracted by an increase in tissue O2 extraction (Bain et al., 2014). This is due to O2 
extraction being inversely proportional to blood flow assuming CMRO2 is constant. 
Unfortunately, because of this interaction, if CBF was reduced by >50%, the resultant O2 
extraction would be unable to sufficiently maintain CMRO2 and cerebral oxygenation 
(COx) (Bain et al., 2014; Gjedde, 2005). As such, any potential increases in CMRO2 will 
severely limit the CBF reserve available to adequately maintain COx. Therefore, Bain et 
al. (2014) hypothesized that with a potential increase in CMRO2 of ~10% and concurrent 
tissue temperature increase of 2°C, CBF could be reduced by ~40-50% and still 
sufficiently maintain COx due to a compensatory increase in O2 extraction. Beyond this 
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threshold of CBF reduction, O2 extraction is at maximum capacity and can no longer 
adequately preserve COx. 
In summary, it has been shown that hyperthermia can cause changes in 
physiological variables such as ventilation (PETCO2) and cerebral hemodynamics 
(CBF/COx) (Figure 1). Furthermore, it is possible that these physiological changes have a 
direct affect on cognitive function when exposed to environmental temperatures causing 
hyperthermia.  
 
 
Figure 1. Schematic representation of the mechanisms and modifying factors causing 
changes in CBF and COx during whole-body hyperthermia (Bain et al., 2014).  
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2.2 Proposed Theories on Cognitive Performance and Thermal Strain  
Current literature suggests that heat exposure causing hyperthermia is associated 
with marked reductions in cognitive ability (Gaoua, 2010). It has been proposed that 
these reductions are due to a number of possible mechanisms ranging from changes in 
arousal to depletion of attentional resources (Hancock & Vasmatzidis, 2003). 
Subsequently, various theories have been proposed in an attempt to explain the reduction 
in cognitive function during heat exposure. 
2.2.1 Arousal Theory 
The first and most widely used model of explaining the effects of hyperthermia on 
cognitive function is the Arousal Theory (Hancock & Vasmatzidis, 2003). This theory 
employs an inverted-U relationship to describe the relationship between arousal level and 
performance (Yerkes-Dodson Law). First described by Yerkes & Dodson (1908), the 
Arousal Theory (Figure 2) postulates that performance reaches a maximal point as 
arousal increases toward an optimal level (Hancock & Vasmatzidis, 2003). However, any 
further increase in arousal beyond this “optimal level” will elicit no further increases in 
quality of performance and, in fact, any movement away from optimal arousal levels will 
generate a subsequent decline in performance (Hancock & Vasmatzidis, 2003). 
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Figure 2. Arousal Theory as described by Hancock & Vasmatzidis (2003). 
 
The inverted-U hypothesis has also been extended to explain the possible effects of 
thermal stress on performance as well (Griffiths & Boyce, 1971; Provins, 1966). As core 
body temperature rises above baseline levels, there is initially an associated increase in 
arousal level (Hancock & Vasmatzidis, 2003). However, in compliance with the inverted-
U hypothesis, once a critical threshold in core temperature is reached, performance levels 
plateau and any further increase in core temperature (arousal) will result in performance 
decrements (Hancock & Vasmatzidis, 2003). As outlined by Hancock & Vasmatzidis 
(2003), Provins (1966) was the first to describe a potential relationship between the 
Arousal Theory and performance during heat stress. Provins (1966) argued that the 
Arousal Theory provided the means to consider both the environmental stressor as well as 
the psychological cost of completing the task, such that the collective cost of the 
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environmental/task combination represents the total degree of arousal. This relationship 
has been eloquently displayed in Hancock & Vasmatzidis (Hancock & Vasmatzidis, 
1998)(Figure 3). 
 
Figure 3. Human performance limits with Wet Bulb Globe Temperature (WBGT)/Loge 
(Time). Line representation: A – vigilance performance; B – dual-task performance; C – 
tracking performance; D – simple task performance; E – physiological tolerance 
(Hancock & Vasmatzidis, 1998). 
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2.2.2 Maximal Adaptability Model and Global Workspace Theory  
The Maximal Adaptability Model (MAM) and Global Workspace Theory (GWT) 
are two other theories regarding cognitive performance and thermal stress, respectively. 
These theories can be loosely grouped together as they are both based on the premise that 
humans only possess a limited amount of cognitive resources available to distribute at 
any moment. 
The MAM, originally described by Hancock (1989), postulates that observed 
performance decrements are the direct result of external competition for, and subsequent 
depletion of, attentional resources due to added heat stressors (Kahneman, 1973). Within 
this framework (Figure 4), Hancock & Vasmatzidis (2003) outline stress levels ranging 
from low (hypostress) to high (hyperstress), respectively with a multitude of different 
threshold zones lying between these two extremes. At the epicenter of this stress level 
continuum lies the “normative zone”, wherein the individual is able to complete all tasks 
without any necessary compensatory actions (Hancock & Vasmatzidis, 2003). Beyond 
this normative zone lies the “comfort zone”, wherein cognitive tasks may be completed 
with only minimal adjustments needed to address the specific demands of the task 
(Hancock & Vasmatzidis, 2003).  Hancock & Vasmatzidis (2003) state that as stress 
levels begin to increase beyond the comfort zone (through changes in duration or 
intensity of the stressor), there is a progressive decline in attentional resources. During 
this period of minimal stress (thermal), performance may be maintained or even increased 
due to the implementation of adaptive strategies to effectively use the remaining 
resources (Easterbrook, 1959). However, as stress levels continue to rise, the eventual 
depletion of attentional resources initiates cognitive function decline. The point at which 
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these cognitive decrements begin to occur is identified as the “psychological zone of 
maximal adaptability”. Beyond this zone lies the “physiological zone of maximal 
adaptability,” wherein any further increases in stress level begins to move the body away 
from its physiological homeostasis (Hancock & Vasmatzidis, 2003). 
The MAM considers additional attention resource depletion during heat stress to be 
the cause of observed performance decrements. Furthermore, it allows for a correlation to 
be made between the magnitude of depletion in attentional resources and the onset of 
cognitive decline (Hancock & Vasmatzidis, 2003). The MAM is potentially a more useful 
and comprehensive model than the arousal theory with respect to thermal stress because, 
as Hancock & Vasmatzidis (2003) outlines, it is able to establish a relationship between 
both the psychological and physiological aspects of cognitive performance. 
 
 
Figure 4. Maximal Adaptability Model as proposed by Hancock & Warm (1989). 
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Similarly to the MAM, the GWT (Baars, 1993) proposes that subconscious 
processes, such as temperature regulation, occur in conjunction with the completion of 
cognitive tasks. However, according to the GWT (Baars, 1993), conscious capacity is 
limited and acts to coordinate and manage neuronal resources for the unconscious 
processes. Subsequently, there is a limited resource capacity available to complete 
cognitive tasks due to multiple stimuli all competing for conscious access to the “global 
workspace” (Baars, 1993; Gaoua et al., 2012). It has been suggested (Gaoua, 2010) that 
during heat exposure there is an increased load placed upon a limited conscious 
workspace (task + thermal stress). As such, cognitive function becomes reduced once the 
available resources are insufficient to support both the cognitive task and imposed 
thermal load (Gaoua et al., 2012; Hocking et al., 2001). 
2.3 Executive Functioning Performance and Heat Strain  
Hancock & Vasmatzidis (2003) propose that cognitive function is primarily 
affected by dramatic alterations in the thermal state of the body. Decrements in cognitive 
performance have been observed during increases in both skin (Gaoua et al., 2011; Gaoua 
et al., 2012; Ramsey & Kwon, 1992) and core temperature (Simmons et al., 2008). 
However, the mechanisms through which these decrements occur are vastly different. 
With regards to peripheral temperature changes (skin), it appears that the rate of change is 
the primary factor in affecting concurrent cognitive performance (Gaoua et al., 2012). 
Alternatively, with central (core) temperature changes, both the rate of change as well as 
the absolute value has been show to be contributing factors in cognitive decline (Gaoua et 
al., 2011; Hancock, 1986; Hancock & Vasmatzidis, 2003).  
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2.3.1 Cognitive Performance and Core Temperature 
A recent study by Simmons et al. (2008) examined the effect of increasing core 
temperature and skin temperature, both separately and combined, on cognitive 
performance during passive heat stress (45°C, 50% RH; core temperature = 1.0°C > 
baseline). To test this, participants were asked to perform four cognitive tasks (digit 
vigilance, choice reaction time, rapid visual information processing, and simple reaction 
time) during three different experimental conditions. It was found that independent 
increases in skin temperature did not elicit any changes in cognitive performance, 
whereas simultaneous increases in both skin and core temperature resulted in decreased 
cognitive performance, such that reaction times were increased but with a loss of 
accuracy. These results are in agreement with previous literature (Hancock, 1986) that 
suggests decrements in cognitive performance are only observed when core temperature 
is increased beyond a threshold at which the body can no longer adequately compensate. 
Further evidence of core temperature being an important regulating factor, was the 
recorded lack of change in cognitive performance during an alternative protocol within 
the same study examining head and neck skin cooling (Simmons et al., 2008). Simmons 
et al. (2008) found that skin cooling significantly reduced mean skin temperature, as well 
as feelings of thermal discomfort. However, despite these changes, core temperature 
remained at an elevated level and cognitive indices were unchanged when compared to 
pre-cooling performance values. These results suggest that core temperature is a more 
profound thermal limiting factor to cognitive performance, particularly with a longer 
duration heat exposure. 
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2.3.2 Cognitive Performance and Skin Temperature 
Despite the reported results (Simmons et al., 2008), previous literature (Ramsey & 
Kwon, 1992) has also shown that cognitive decrements occur with short duration heat 
exposures (<30min). It is presumed that with such minimal exposure time, it is unlikely 
that observed cognitive impairments are due to vast alterations in core temperature. 
Taking these conclusions into account, it has been proposed (Hancock & Vasmatzidis, 
2003; Pilcher et al., 2002) that cognitive function is also influenced, in large part, by skin 
temperature variations. These observed changes in cognitive function resulting from 
manipulations in skin temperature have been generally attributed to the alliesthesial 
effect. First described by Cabanac & Duclaux (1970), the alliesthesial effect proposes that 
a given thermal stimulus may induce feelings of pleasure or displeasure, depending on 
the ambient temperature. A stimulus is considered pleasurable when it facilitates 
adaptations within the body to return it to, or prevent further deviation from, its 
homeostatic state (Cabanac, 1971; Gaoua et al., 2012). Conversely, an unpleasant 
stimulus will begin to upset the homeostatic balance within the body (Cabanac, 1971; 
Gaoua et al., 2012).  
In support of the alliesthesial effect theory, Gaoua et al. (2012) examined the 
hypothesis that an individual’s subjective state, measured through changes in skin 
temperature, affects cognitive performance without a change in core body temperature. 
To do this, Gaoua et al. (2012) asked participants to complete a set of cognitive tasks 
while being exposed to two different environmental conditions; HOT (50°C/30%RH) and 
CON (24°C/30%RH). Participants were required to perform two distinct cognitive tasks; 
an executive planning task (One Touch Stockings of Cambridge – OTS) and a reaction 
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time test (Choice Reaction Time – CRT). Furthermore, there were two complexity levels 
(simple/complex) within each of the aforementioned tasks (OTS-4/OTS-6; CRT/5-CRT). 
Results from Gaoua et al. (2012) showed that there was a significant increase in skin 
temperature (+2.82°C) in the HOT vs. CON, with no significant difference in core 
temperature between the conditions. Furthermore, Gaoua et al. (2012) found that 
participants perceived themselves to be hotter, as indicated by an increase in thermal 
sensation, and less comfortable, indicated by an increase in thermal comfort, in the HOT 
condition compared to the CON condition. In regard to the cognitive testing, there were 
no significant differences in reaction time or accuracy measures between CRT and 5-
CRT regardless of condition. Additionally, there were no significant difference in OTS-4 
accuracy and latency measures. However, with the more complex OTS-6, performance 
was significantly better in the CON than the HOT condition (Gaoua et al., 2012).  
Taking into account these results, Gaoua et al. (2012) proposed that the decrements 
seen in the OTS-6 during the HOT condition were most likely due to displeasureable 
feelings instigated by a sudden change in environmental conditions (alliesthesial effect). 
As outlined by Gaoua (2010), sudden changes in environmental conditions, such as heat 
exposure, may cause an additional cognitive load. This, in turn, increases the attentional 
demands leaving less available resources to successfully complete a concurrent cognitive 
task. Gaoua et al. (2012) revealed that exposure to the HOT condition, and subsequent 
~3°C increase in skin temperature caused high feelings of displeasure, thus causing 
homeostatic imbalance within the body. Gaoua et al. (2012) further concluded that the 
observed decrements in cognitive function could not have been due to core temperature 
as there were no significant changes between conditions.  
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2.3.3 Combined effect of Skin and Core Temperature on Cognitive Performance  
Gaoua et al. (2011) examined the effects of prolonged passive heat stress on 
neuromuscular and cognitive function. However, for the purpose of this literature review, 
the primary focus will be on the cognitive function testing. To test this, participants were 
required to perform identical experimental protocols in two different environmental 
settings. The control (CON) session required participants to enter an environmental 
chamber set at 24°C/40% RH and perform the OTS of different complexity levels (OTS-
4 and OTS-6). The hot (HOT) session required participants to enter an environmental 
chamber set at 44°C/40% RH, however this ambient temperature was adjusted to ensure 
that participants core temperature reached a target value for each separate assessment 
period (T1 ~37.3°C; T2 ~37.8°C; T3 ~38.3°C; T4 ~38.8°C). 
It was found (Gaoua et al., 2011) that OTS-4 results did not show any significant 
changes between conditions. However, OTS-6 results were significantly improved in 
CON condition vs. HOT condition (Figure 5). More specifically, it was observed that 
decrements in the OTS-6 occurred at the onset of heat exposure in participants with a 
normothermic core temperature. This suggests that complex cognitive performance can 
be affected by rapid changes in environmental temperature. As previously discussed, this 
sensitivity of cognitive function to changes in skin temperature could be partly related to 
the feelings of pleasure or displeasure that they induce (alliesthesial effect). Therefore, 
the increase in skin temperature observed at the onset of heat exposure generated an 
unpleasant stimulus that could be considered an additional cognitive load that draws upon 
the available resources. Subsequently, despite a rapid increase in skin temperature upon 
heat exposure (added cognitive load), there were sufficient attentional resources available 
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to successfully complete the less complex OTS-4 (Gaoua et al., 2011). Interestingly, 
during increased core temperatures at T2 (37.8°C) and T3 (38.3°C), there were no 
changes in cognitive performance regardless of OTS complexity (Gaoua et al., 2011). 
With regard to skin temperature, although there was a significant increase from T1, there 
was little variation in either the T2 or T3 assessment periods. Gaoua et al. (2011) 
suggested that this likely means the rate of change in skin temperature rather than the 
absolute temperature, is a more important factor when considering the effects on 
cognitive function.  
During the final stage, T4 (38.8°C), complex task performance was significantly 
impaired (Gaoua et al., 2011). It has been previously suggested (Hancock, 1986) that 
cognitive performance decreases when there is a dynamic and uncompensable change in 
core temperature. Therefore, it was concluded that the decrements in cognitive function 
seen during the final stage were likely to have originated from the additional thermal load 
imposed by the dynamic changes in core temperature (Gaoua et al., 2011). As previously 
discussed, this finding is confirmed through the absence of detrimental effects on the 
OTS-4 results, which requires fewer resources to complete the task successfully, due to 
hyperthermia (Gaoua et al., 2011). 
 
Figure 5. OTS-6 performance (CON – white; HOT – black) (Gaoua et al., 2011). 
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In summary, it would appear that cognitive function is affected by some 
combination of skin and core temperature. In the case of short duration heat stress (<30 
min), where changes in core temperature have not yet been elicited, skin temperature 
appears to be a primary mechanism causing cognitive performance decline. Whereas, 
during longer, more intense heat exposure, it is generally accepted that core temperature 
has a stronger influence on cognitive function capabilities.  
2.3.4 Possible Effects of PETCO2 and Cerebral Blood Flow 
It can be generally concluded that observed reductions in cognitive function upon 
initial heat exposure are likely due to the alliesthesial effect caused by rapid changes in 
skin temperature (Gaoua et al., 2011; Gaoua et al., 2012). However, the mechanisms 
causing cognitive decrements during heat stress of longer duration are more difficult to 
distinguish. Previous research has shown an increase in CBF during cognitive activation 
(Kelley et al., 1992; Szabo et al., 2011); therefore, it follows that an inhibition of CBF 
may cause a subsequent decline in cognitive performance. Previous literature examining 
cognitive function during heat stress has concluded that observed decrements in cognitive 
function are primarily due to thermal deviations from body homeostasis. That is, the 
additional thermal load as a result of alterations in skin and core temperature competes 
with cognitive resources required to complete complex tasks. However, previous 
literature has largely failed to consider the hyperthermic effect on ventilation (primarily 
the changes in PETCO2 caused by hyperventilation). Moreover, this hyperventilation-
induced hypocapnia causes cerebral vasoconstriction, which results in a significant 
reduction in CBF and oxygen delivery (Brothers et al., 2009; Nybo et al., 2014). Taking 
these effects into consideration, it is possible that cognitive decrements observed during 
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heat stress may be related to the changes in hypocapnia and subsequent alterations in 
cerebral hemodynamics. Due to the large influence of hyperthermia on ventilation 
(PETCO2), and subsequently, the cerebral vasculature, it is plausible that any homeostatic 
disturbances in these variables (PETCO2/CBF) may affect cognitive function during 
prolonged heat exposure. 
A study by Schlader et al. (2013) examined the overall effects of hyperthermia on 
CBF during cognitive activation. Participants underwent cognitive testing (test of 
working memory – nBack test) during normothermic (34°C water perfusion - LCG) and 
hyperthermic (49°C) conditions. Hyperthermia was defined by Schlader et al. (2013) as 
an increase in core temperature by ~1.3°C. It was found that there was no significant 
change in CBF during cognitive activation with heat stress, which, in turn, had no 
negative effect on cognitive performance (Schlader et al., 2013). However, it was 
speculated by the authors (Schlader et al., 2013) that there were a multitude of reasons as 
to why this result occurred. First, it was hypothesized that the nBack cognitive test did 
not evoke the necessary cognitive overload necessary to elicit performance decrements 
with hyperthermia. Secondly, the hyperthermia-induced hypocapnia elicited in the study 
(Schlader et al., 2013) was relatively low (~4 mmHg). It is possible that such a minimal 
hypocapnic stimulus was not sufficient to evoke a strong cerebral vasoconstriction 
response, and subsequently there was only a moderate decrease in baseline CBF (~14%).  
In another study, Ross et al. (2012) investigated the integrative effects of 
progressive, passive hyperthermia on CBF and alterations in motor drive. However, for 
the purpose of this literature review, only the hyperthermic effects on CBF and PETCO2 
will be discussed. During the study, experimental measurement were made at baseline 
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(37.1°C ± 0.3°C) and at 0.5°C increments in core temperature until participants reached 
their limit of thermal tolerance (39.1°C ± 0.4°C). Passive heating was achieved by 
circulating 50 ± 1°C water through a liquid conditioning garment. Ross et al. (2012) 
found that PETCO2 gradually declined throughout heating as expected with increased 
ventilation (Ve) (occurring +1.0°C). However, PETCO2 only became significantly 
different from baseline at an approximate 1.5°C increase in core temperature (Figure 6). 
Similarly, CBFv, indicated by MCAv, decreased throughout the heating protocol, 
becoming significantly different from baseline at +1.0°C. Furthermore, COx was 
significantly decreased from baseline measures at +2.0°C. 
 
Figure 6. PETCO2 changes with passive heat stress (Ross et al., 2012). 
 
Examining the implications of Gaoua et al. (2011), Ross et al. (2012) and Schlader 
et al. (2013) provides a potential explanation of the observed cognitive decline during 
prolonged heat exposure. It is possible that more mentally demanding tasks (complex 
tasks) require a larger increase in CBF to support the metabolic demands (Schlader et al., 
2013). With regard to Ross et al. (2012), they found that reductions in CBF only became 
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significant once core temperature had increased by 1.0°C above baseline values. 
Furthermore, PETCO2 changes only became significantly different once core temperature 
had risen 1.5°C above baseline levels (~38.6°C). Similarly, with the study by Gaoua et al. 
(2011), cognitive decrements, apart from the initial exposure to heat stress, only occurred 
at a core temperature 1.5°C above baseline (~38.8°C). When integrating the results of 
these studies (Gaoua et al., 2011; Ross et al., 2012; Schlader et al., 2013), it appears that 
there may be a relationship between the observed decreases in PETCO2/CBF and 
reductions in complex cognitive task performance with concurrent hyperthermia.  
Research has shown that cognitive decrements occur with changes in skin (Gaoua 
et al., 2011) and core (Simmons et al., 2008) temperature. Recent results (Gaoua et al., 
2011; Ross et al., 2012; Schlader et al., 2013) also suggest that changes in the cerebral 
vasculature during heat stress may also play a role in observed cognitive decline during 
prolonged heat stress. Ultimately, it is likely that changes in cognitive function with 
hyperthermia occur due to a multitude of physiological and psychological factors, and 
that these factors are symbiotic and not mutually exclusive. 
2.4 Gaps in the Literature  
2.4.1 Limitations of Previous Research  
Current research examining the effects of hyperthermia on cognitive performance 
lacks a truly stressful heat stress protocol. With respect to Gaoua et al. (2011), it is 
possible that their study did not produce a stressful enough heat exposure to induce 
cognitive decrements at all time points. Having participants core temperature increase at 
such a gradual rate (0.5°C every 90 min) may not have produced a stressful enough 
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thermal strain to induce cognitive decrements during the middle stages. Similarly, 
although skin temperature gradually increased over the course of the entire trial, no 
cognitive decrements after T1 were attributed to increasing skin temperature. From this, 
Gaoua et al. (2011) ultimately suggested that it might be the rate of change rather than the 
absolute temperature that plays a more prominent role in cognitive performance. 
Current research has not elicited a truly meaningful reduction in CBF as a result of 
hyperthermia-induced hypocapnia, which may be needed to induce a noticeable decline 
in cognitive function. As observed by Ross et al. (2012), changes in PETCO2 only begin at 
~1.5°C increase in core temperature with passive heat exposure, which would explain the 
minimal reduction in PETCO2 observed by Schlader et al. (2013). Since there was not a 
significant decline in PETCO2, there would be minimal change in the cerebral vasculature 
and therefore no substantial reduction in CBF. 
Finally, previous research examining similar changes in the cerebrovasculature 
(Schlader et al., 2013) has not utilized an appropriate mental task during hyperthermia to 
adequately stress cognitive performance. It is imperative that a test battery utilizing a 
significant quantity of neuronal resources is administered in order to induce the necessary 
overload, or depletion, to elicit hyperthermia-induced decrements in cognitive 
performance.  
2.4.2 Role of Indomethacin 
The use of indomethacin as a pharmacological intervention is relatively novel in the 
literature when examining CBF. Indomethacin is a non-selective cyclooxygenase 
inhibitor that can effectively decrease CBF and alter the cerebrovascular CO2 reactivity to 
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both hypo- and hypercapnia (Ainslie & Duffin, 2009). By using Indomethacin, it is 
possible to selectively decrease CBF without any concurrent changes in significant 
physiological variables. This allows for the independent manipulation of CBF and 
PETCO2 with concurrent heat stress.  
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3 Thesis Objectives and Hypotheses 
3.1 Objectives 
The objectives of this study are: 
1. Examine the effects of passive heat stress (Tre ~2.0°C above baseline) on 
simple vs. complex cognitive tasks. 
2. Determine the effects of hyperthermia-induced hyperventilation and 
subsequent decline in PETCO2 (hypocapnia) on simple vs. complex 
cognitive tasks. 
3. Determine the separate effects of PETCO2 and CBF via end-tidal forcing and 
a pharmacological intervention on simple vs. complex cognitive tasks with 
concomitant heat stress (Table 1). To identify the individual effects of 
PETCO2, PETCO2 will be clamped at baseline through end-tidal forcing to 
prevent the natural decline in PETCO2 during hyperthermia-induced 
hyperventilation. To identify the individual effect of CBF, a 
pharmacological-induced reduction will be utilized (indomethacin). 
3.2 Hypotheses 
The hypotheses of this study are: 
1. Complex cognitive task performance will be impaired post wash-in during 
the Indo trial only due to significant reductions in CBF. 
2. Complex cognitive task performance will be impaired upon initial exposure 
to heat stress (no change in core temperature from baseline) independent of 
changes in PETCO2, CBF or Tre. 
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3. Complex cognitive task performance will be reduced during the final stage 
of heat stress exposure (~2.0°C increase in core temperature from baseline) 
independent of changes in PETCO2 or CBF. 
 
 
Table 1. Physiological manipulations for each experimental condition. 
Protocol  Physiological Manipulation 
Poikilocapnic Hyperthermia   Tc  CBF  ETCO2 
Isocapnic Hyperthermia   Tc n/c CBF n/c PETCO2 
Isocapnic Hyperthermia + Indomethacin   Tc  CBF n/c PETCO2 
Increase (); Decrease (); No Change (n/c); Core Temperature (Tc)  
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4 Methods 
4.1 Participants 
Eight healthy males from Brock University and the surrounding community 
volunteered to participate in this study. The mean ± SD age, height, mass and body mass 
index were 26 ± 8 years, 176.8 ± 6.8 cm, 67.47 ± 8.68 kg and 21.5 ± 1.5 kgm-2, 
respectively. Due to sex differences in cerebrovascular CO2 reactivity, only males were 
recruited. Participants were also excluded if they had a diagnosed medical condition(s) 
(cardiovascular, respiratory, neurological), or any contraindications to non-steroidal anti-
inflammatory drugs (NSAIDs). 
4.2 General Methods 
4.2.1 Skin Fold Measurements 
Skin fold thickness was measured with a caliper at seven sites (triceps, subscapula, 
abdomen, supra-iliac crest, abdomen, thigh, and medial calf) with the results used to 
calculate body fat (BF) composition. BD = 1.11200000 – 0.00043499 (X1) + 0.00000055 
(X1)
2 – 0.00028826 (X3), where X1 represents the sum of chest, axilla, triceps, 
subscapula, abdomen, suprailium, front thigh skinfolds and X3 represents age (Jackson & 
Pollock, 1978). Once BD was obtained, it was then input into the following equation; 
%BF = [4.950 / BD (kg·m-3) – 4.500] x 100 (Siri, 1961). 
4.2.2 Hydration Status 
Before and after each experimental session hydration status was assessed by 
measuring urine specific gravity with a refractometer (PAL-10S, Atago, USA). A 
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euhydration threshold of ≤ 1.02 was used as a cut-off value (Armstrong, 2005). If 
participants exceed this predefined threshold they were asked to consume 0.5 L of water 
and hydration was reassessed 30min later. If euhydration was confirmed at this point, 
testing began. If participants were still not adequately hydrated the experimental session 
was rescheduled for a later date.  
4.2.3 Temperature Measurements 
During each experimental trial, rectal temperature (Tre) was continuously measured 
using a thin and flexible general-purpose thermistor (Mon-A-Therm Core, Mallinkrodt 
Medical), inserted (by the participant) 15 cm beyond the anal sphincter.  
Mean skin temperature (?̅?𝑠𝑘) was measured with flexible thermistors (PVC-T-24-
190, OMEGA Environmental Inc.) taped to the skin and calculated using a four point 
weighted averages equation with thermistors placed on the chest, forearm, thigh and calf. 
?̅?𝑠𝑘 = (T1 x 0.3 + T2 x 0.3 + T3 x 0.2 + T4 x 0.2), where T1 = chest temperature; T2 = 
forearm temperature; T3 = thigh temperature; T4 = calf temperature (Ramanathan, 1964).  
4.2.4 Blood Pressure Measurements 
Beat by beat blood pressure was calculated from the blood pressure waveform 
using finger photoplethysmography (Nexfin, bmeye), with a finger cuff placed directly 
over the middle finger on the left hand. Blood pressure measurements were used to 
ensure that physiological parameters remain within a safe range during experimentation. 
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4.2.5 Electrocardiogram 
To measure heart rate, a 3-lead electrocardiogram (ECG; BioAmp, AD 
Instruments) was used. Lead sites were shaved and cleaned with rubbing alcohol prior to 
placement of the electrodes.  
4.2.6 Middle Cerebral Artery Flow Velocity Measurements 
Cerebral blood flow velocity in the middle cerebral artery (MCA) was measured 
non-invasively by a 2-MHz transcranial Doppler (TCD) ultrasound probe (ST3, Spencer 
Technologies), attached bilaterally to a headband and secured anterior to the zygomatic 
arch, rostral of the pinna. Doppler probes were placed over the temporal windows (near 
the ear) and remained in place throughout the experimental protocol. The MCA was used 
in the current study as measurements of MCAv via TCD have been validated with 
prostaglandin inhibition during 100mg oral dose of indomethacin (Xie et al., 2006). 
Furthermore, previous research has revealed similar CBF changes in both the MCA and 
ACA during cognitive activation of a similar executive functioning task (Frauenfelder et 
al., 2004). 
4.2.7 End-Tidal Gas Measurements 
A soft silicone facemask was worn to collect expired gases for determining end-
tidal partial pressure of oxygen (PETO2) and PETCO2 concentrations using a gas collection 
system. Participants were permitted to briefly remove the mask and drink if they required 
fluid during the experimental protocol. However, fluid ingestion was only encouraged to 
ensure participants reached the necessary ~2.0°C increase in Tre. 
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An end-tidal forcing system was used to control the desired PETCO2 levels for the 
participant throughout each experimental condition. Measurements of the concentration 
of expired PETCO2 are derived from a standard metabolic cart. These expired values were 
compared to the desired values and a computer subsequently controlled the delivery of 
the correct volume and concentration of oxygen, carbon dioxide, and nitrogen for the next 
breath. This is a commonly used approach for controlling breathing gases since it 
provides excellent control of inspired gas concentrations (Koehle et al., 2009). 
To control for the influence of PETCO2 on cerebral blood flow, PETCO2 levels were 
allowed to either fluctuate naturally (poikilocapnia), which would reduce the PETCO2 
down to 30-32 mmHg with hyperventilation, or the end-tidal forcing system was used to 
maintain PETCO2 at resting baseline levels (isocapnia) during conditions (Steinback & 
Poulin, 2007).  
4.2.8 Liquid Conditioning Garment 
Participants wore a liquid conditioning garment (LCG; BCS 4 Cooling System, 
Allen Vanguard) consisting of 1/8” diameter Tygon tubing sewn over a close-fitting 
stretchable shirt covering the torso, arms, and legs. The head, hands, and feet were left 
uncovered. To promote maximum heat exchange between the skin and the garment, 
participants wore only shorts during the experiments. Inlet water temperature of the 
garment, with a flow rate of 1.5 Lmin-1, was controlled by a recirculating chiller/heater 
with a resolution of 0.1°C. During passive heating, a water temperature of ~50°C was 
used to increase Tsk up to ~40°C and Tre up to ~2.0°C above baseline or participant 
tolerance. Furthermore, an impermeable rain-suit was worn over the LCG and a thermal 
blanket placed on top of the participant during the experimental trial to prevent heat loss. 
  32 
This approach of heating has been previously used for similar durations as those 
described in the current experiment (Ross et al., 2012).  
4.2.9 Indomethacin 
An indomethacin pill(s) was ingested at a dose of 1.2 mg·kg-1 body mass up to a 
maximum dose of 100 mg. The maximum daily dose of indomethacin is 200 mg 
(Canadian Pharmacists Association, 2013); however, a single dose of no more than 100 
mg is advised. Indomethacin is a reversible and safe cyclooxygenase inhibitor (NSAID), 
which decreases cerebral blood flow without concomitant changes in metabolic rate, 
cerebral pH or plasma catecholamines. This unique feature makes indomethacin an ideal 
tool for investigating the effect of cerebral blood flow independent of the control of 
breathing in humans. The indomethacin dosage was supplemented with a 150 mg over 
the counter antacid (ranitidine; trade name Zantac) to counteract possible side effects of 
gastrointestinal stress. A 150 mg dose of ranitidine is typically used to treat acid reflux 
(Canadian Pharmacists Association, 2013). 
4.2.10 Cognitive Function Testing 
To examine executive function, the One-Touch Stockings (OTS) of Cambridge 
(CANTAB, Cambridge Cognition Ltd.) was administered (Appendix A). The specific test 
mode used in the current study was the 7-choice-24 mode. The OTS test display (Figure 
7) consists of two separate illustrations containing three coloured balls (red, blue and 
green), which are presented so that they are perceived as stacks of balls in a stocking/sock 
suspended from a line (Cambridge Cognition Ltd., 2014). The OTS consists of two 
distinct testing sections. During the first portion of the test, the participant must use the 
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coloured balls in the lower display to reproduce the pattern presented in the upper display 
in the least amount of moves possible. The participant completed a round of testing that 
consists of four difficulty levels: one move, two moves, three moves, and four moves, 
respectively. The second part of the OTS test required the participant to work out how 
many moves it will take to solve the problem. They would then touch the corresponding 
box, with the indicated number of moves, to indicate their response (Cambridge 
Cognition Ltd., 2014). 
The OTS has four distinct outcome measure: 1) the number of problems solved on 
the first choice (FCS); 2) latency to first choice (FCL); 3) mean choices to correct answer 
(MCC), and; 4) mean latency to correct answer (MLC). The OTS test took approximately 
10 min to complete (Cambridge Cognition Ltd., 2014). OTS problems consisting of four 
(OTS-4) and six moves (OTS-6) to complete were examined to assess changes in simple 
(OTS-4) and complex (OTS-6) executive functioning performance.  
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Figure 7. CANTAB – OTS Screen Shot. 
4.2.11 Thermal Comfort/Thermal Sensation 
To examine any potential changes in perceptual measures of the ambient 
temperature, values of Thermal Comfort (TC) and Thermal Sensation (TS) were taken at 
baseline, post wash-in, initial heat exposure (IHE) and thermal tolerance/limit (T-LIM). 
TC and TS were reported on 1-4 and 1-7 scales, respectively (Gagge et al., 1967). 
4.3 Experimental Protocol 
4.3.1 Screening Session 
Before being allowed to participate, participants were asked to fill out a standard 
screening questionnaire detailing their current health status, use of medications and 
history of lung, heart, muscle and/or kidney disease (Appendix B). This questionnaire 
was completed in the presence of Dr. Matthew Greenway, MD, Ph.D.  
4.3.2 Familiarization Session 
For the familiarization session, participants underwent an entire experimental trial 
minus any of the specific manipulations. This session was to ensure that participants were 
comfortable with the heating protocol and consisted of passive heating using the LCG 
(water temperature ~50°C) to increase Tre by ~2.0°C or to T-LIM. During this session, 
participants were also familiarized with the OTS software and touchpad (performed the 
7-choice-15 test mode). 
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4.3.2 Experimental Sessions 
Upon arrival to the laboratory, participants began by changing into comfortable 
clothing (loose fitting t-shirt, pants/shorts) and provided a urine sample for hydration 
analysis. After ensuring adequate hydration, the rectal thermistor was self-inserted by the 
participants. When participants returned, a baseline 30 s Purdue Pegboard test was 
administered. Once completed, participants were instrumented with the LCG, skin 
temperature thermistors, a soft silicone mask for delivery of inspired air mixture and end-
tidal gas concentrations, the finger blood pressure cuff, ECG, and TCD. During this 
instrumentation phase, participants were supine on a soft table. Upon instrumentation, 
participants underwent pre wash-in baseline testing consisting of baseline physiological 
measurements followed by completing the OTS cognitive test. 
Participants then underwent the wash-in phase of the placebo (visits “a” and “b”) or 
the indomethacin (visit “c”), the order of which was randomized. The wash-in period 
took ~90 min allowing sufficient time for the drug concentration to peak in the blood 
stream (Canadian Pharmacists Association, 2013). During this time participants and 
rested quietly in the lab. 
Following the wash-in period, participants completed a second 30 s Purdue 
Pegboard test. Once this was completed, participants were exposed to (a) poikilocapnic 
hyperthermia (Poikilo), (b) isocapnic hyperthermia (Iso) or (c) isocapnic hyperthermia 
and indomethacin (Indo) interventions. During each condition, core temperature was 
passively increased until T-LIM or to a maximum of ~2.0°C. Cognitive testing was 
administered at baseline, post wash-in, IHE (≥ 3.0°C in Tsk) and at T-LIM.  
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Immediately following the final experimental procedure, participants performed 
one last 30 s Purdue Pegboard test. Once this test was completed participants de-
instrumented; however, they were monitored for 30 min throughout recovery to ensure 
that they were symptom free from any possible side-effects caused by the experimental 
protocol. All experimental procedures were performed with participants on a cushioned 
bench in a semi-recumbent position (~135° angle). Schematic overview of the 
experimental protocol is shown in Figure 8. 
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Figure 8. Schematic outline of experimental protocol.  
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(30 min) 
a) Poikilocapnic hyperthermia 
b) Isocapnic hyperthermia, or 
c) Isocapnic hyperthermia + indomethacin 
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4.4 Statistical Analysis  
Individual two-way repeated measures ANOVA analyses were conducted to assess 
the change in respiratory, cerebrovascular, cardiovascular and cognitive responses 
between baseline, post wash-in, IHE and T-LIM across the three experimental conditions 
(Poikilo, Iso, Indo). Sphericity was assessed using Mauchly’s test of sphericity, and if 
violated (p ≤ 0.05), data was assessed using a Greenhouse-Geisser adjustment. Pair-wise 
comparisons, using a Bonferroni correction, were used to identify main effects. Any 
significant interactions (time x condition) were assessed using separate repeated measures 
ANOVA.  
All statistical analyses were conducted using SPSS 20 (SPSS Inc., Chicago, Illinois, 
USA). Statistical significance was set at p = 0.05. Data is reported in text and tables as 
mean ± SD. 
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5 Results 
All participants arrived at the laboratory in a euhydrated state (baseline USG, 1.012 
± 0.005); however, USG was slightly, but not significantly, increased at T-LIM (to 1.015 
± 0.003; p = 0.14). Body mass was significantly reduced from baseline to T-LIM (-2.2%; 
from 67.47 ± 8.68 to 65.98 ± 8.39 kg, p < 0.001). There were no significant differences in 
USG or body mass between conditions at any time point. Purdue Pegboard scores were 
unchanged across all conditions and time points.   
5.1 Thermal and Perceptual Responses 
No significant difference (p > 0.05) in baseline measurements were observed 
between conditions for Tre, ?̅?𝑠𝑘, TC or TS. Mean total heating time from post wash-in to 
T-LIM was 97.46 ± 35.49 min, during which time Tre increased by 1.48 ± 0.34°C (p < 
0.001) from post-wash in (36.88 ± 0.27°C) to T-LIM (38.36 ± 0.37°C). Mean total 
heating time was moderately, but not significantly, lower in Indo (86.75 ± 36.19 min) 
when compared to Poikilo (102.00 ± 33.71 min, p = 0.183) and Iso (103.63 ± 38.64 min, 
p = 0.132) conditions. 
5.1.1 Thermal Measures 
Tre (Figure 9a) showed a significant main effect for time (p < 0.001) with no main 
effect for condition (p = 0.177) or significant interaction effect (p = 0.303). Tre was not 
significantly different between baseline (36.88 ± 0.27°C) and post wash-in (36.95 ± 
0.26°C); however it was statistically different between post wash-in and IHE (36.86 ± 
0.22°C, p = 0.022). Furthermore, it was also significantly higher at T-LIM (38.37 ± 
0.37°C) relative to all other time points (p < 0.001). 
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Similarly, ?̅?𝑠𝑘 , presented in Figure 9b, was not statistically different between 
baseline and post wash-in (32.43 ± 0.41 vs. 33.08 ± 0.43°C; p = 0.157); however, it was 
significantly increased relative to both baseline and post wash-in at both IHE (37.02 ± 
0.35°C, p < 0.001) and T-LIM (39.21 ± 0.43°C, p < 0.001). Furthermore, ?̅?𝑠𝑘  was 
significantly different between IHE and T-LIM (p < 0.001). Changes in ?̅?𝑠𝑘 did not have a 
significant main effect for condition (p = 0.248) or a significant interaction effect (p = 
0.767). 
5.1.2 Subjective Measures 
Thermal Comfort (Figure 9c) showed no interaction effect (p = 0.739) or main 
effect for condition (p = 0.657); however, there was a main effect for time (p < 0.001). 
TC was significantly increased at T-LIM compared to all time points (3.9 ± 0.2, p < 
0.001). It was also statistically different between IHE (1.7 ± 0.6), post wash-in (1.1 ± 0.2; 
p < 0.006) and baseline (1.0 ± 0.0, p = 0.10); however, it remained relatively unchanged 
between baseline and post wash-in (p = 0.351). 
Thermal Sensation (Figure 9d) only showed a significant main effect for time such 
that it was significantly increased at T-LIM compared to all time points T-LIM (6.9 ± 0.1, 
p < 0.001). Furthermore, IHE (5.4 ± 0.4, p < 0.001) was also significantly higher than 
baseline (3.8 ± 0.2, p < 0.001) and post wash-in (4.3 ± 0.4, p < 0.001); however, it 
remained unchanged between baseline and post wash-in (p = 0.153).  
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Figure 9a. Mean Tre with increasing 
passive heat stress between the three 
experimental conditions. Matching 
letters indicate significant differences 
between measurement periods (p < 
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5.2 Respiratory, Cerebrovascular and Cardiovascular Responses 
5.2.1 Respiratory Measures 
Ve (Table 2) showed a main effect for time (p = 0.015); however did not display a 
main effect for condition (p = 0.230) or significant interaction (p = 0.236). Overall Ve 
was only significantly different at baseline when compared to all other time points (p < 
0.05). Furthermore, Ve was only significantly different at T-LIM between Poikilo (17.49 
± 6.51 l∙min-1) and Iso (24.38 ± 8.74 l∙min-1, p = 0.007); it was not statistically different 
between Poikilo and Indo (21.13 ± 8.38 l∙min-1, p = 0.310) or Iso and Indo (p = 0.447). 
There was a significant interaction effect for PETCO2 (p = 0.006)(Figure 10a) and a 
significant main effect for time (p < 0.001); however, no main effect for condition was 
found (p = 0.397). At baseline, PETCO2 (Table 2) was not significantly different (p > 
0.05) between all three conditions (46.01 ± 2.48 mmHg, 45.07 ± 1.70, 44.35 ± 3.42 
mmHg for Poikilo, Iso and Indo respectively). Post wash-in, there was a significant 
reduction in PETCO2 in the Indo condition (43.69 ± 2.46 mmHg) when compared to 
Poikilo (46.04 ± 1.87, p = 0.021); however, there was no significant difference between 
Poikilo and Iso (44.42 ± 3.73 mmHg, p = 0.879) or Iso and Indo (p = 1.000).  
There were no significant differences (p > 0.05) between any of the conditions 
(44.53 ± 3.88, 45.02 ± 1.90, 43.43 ± 2.07 mmHg for Poikilo, Iso and Indo, respectively) 
upon IHE with respect to PETCO2. At T-LIM, PETCO2 was significantly reduced in the 
Poikilo condition (36.73 ± 3.59 mmHg) when compared to both Iso (42.75 ± 4.13 mmHg, 
p = 0.015) and Indo (41.21 ± 3.71 mmHg, p = 0.034). There was no statistical difference 
between Iso and Indo at T-LIM (p = 1.000).  
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5.2.2 Cerebrovascular Measures 
MCAv (Table 2) showed significant main effects for time (p < 0.001) and condition 
(p < 0.001) as well as a significant interaction effect (p < 0.001)(Figure 10b).  
Similar values in MCAv were measured at baseline between all three experimental 
trials (74.12 ± 6.10, 68.12 ± 6.66, 70.83 ± 7.87 cm·s-1 for Poikilo, Iso and Indo, 
respectively). In comparison to baseline values, MCAv remained unchanged in Poikilo 
(73.41 ± 5.67 cm·s-1) and Iso (69.88 ± 6.34 cm·s-1) post-wash in (p = 0.127); however, 
MCAv was significantly reduced in the Indo trial (46.42 ± 5.96 cm·s
-1, p < 0.001).  
With respect to IHE, MCAv was significantly lower during the Indo trial (45.96 ± 
5.53 cm·s-1) compared to both Poikilo (69.82 ± 6.97 cm·s-1, p < 0.001) and Iso (63.92 ± 
6.95 cm·s-1, p = 0.001), with no significant differences between Poikilo and Iso (p = 
0.068).  
Finally, at T-LIM, MCAv appeared to be lower in the Indo trial (46.07 ± 7.33 cm·s
-
1); however, this difference was not statistically different from either Poikilo (51.70 ± 
6.39 cm·s-1, p = 0.252) or Iso (55.10 ± 6.87 cm·s-1, p = 0.113). There was also no 
significant difference between Poikilo and Iso conditions with regards to MCAv at T-LIM 
(p = 1.000). 
5.2.3 Cardiovascular Measures 
HR showed significant interaction effect (p = 0.004)(Figure 10c), as well as 
significant main effects for time (p < 0.001) and condition (p = 0.002).  
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There were no significant differences between Poikilo (65.7 ± 13.1 b∙min-1), Iso 
(66.4 ± 10.2 b∙min-1), or Indo (66.0 ± 10.9 b∙min-1) trials at baseline measurement (p > 
0.05).  
At post wash-in, HR was statistically significant between Indo (53.3 ± 6.2 b∙min-1) 
and Poikilo (61.3 ± 8.7 b∙min-1, p = 0.007), as well as Indo and Iso (62.5 ± 7.5, p = 
0.003); however, it was not statistically different between Poikilo and Iso (p = 1.000). 
Upon IHE, HR was again significant different between Indo (62.0 ± 8.1 b∙min-1) 
and Poikilo (71.6 ± 9.8 b∙min-1, p = 0.032), and Indo and Iso (73.1 ± 10.5 b∙min-1, p = 
0.026). HR was not statistically different between Poikilo and Iso at IHE (p = 1.000). 
Finally, at T-LIM, HR was statistically different between Poikilo (114.4 ± 20.5 
b∙min-1) and Iso (125.0 ± 21.4 b∙min-1, p = 0.049) as well as nearly significant between 
Iso and Indo (114.9 ± 17.2, p = 0.052); however, it there was no significant difference 
between Poikilo and Indo (p = 1.000).  
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Table 2. Respiratory and cerebrovascular responses to each experimental condition. 
  Baseline Post Wash-in IHE T-LIM 
Poikilocapnia      
Ve, L∙min-1 
PETCO2, mmHg 
MCAv, cm∙s-1 
 13.62 ± 3.87 
46.01 ± 2.48 
74.12 ± 6.10 
16.18 ± 5.25 
46.04 ± 1.87 
73.41 ± 5.67 
16.21 ± 5.73 
44.53 ± 3.88 
69.82 ± 6.97 
17.59 ± 6.51 
36.73 ± 3.59a 
51.70 ± 6.39b 
Isocapnia      
Ve, L∙min-1 
PETCO2, mmHg 
MCAv, cm∙s-1 
 17.13 ± 4.87 
45.07 ± 1.70 
68.12 ± 6.63 
17.89 ± 4.14 
44.42 ± 3.73 
69.88 ± 6.33 
19.18 ± 4.86 
45.02 ± 1.90 
63.92 ± 6.95 
24.38 ± 8.74 
42.75 ± 4.13 
55.10 ± 6.87b 
Indomethacin      
Ve, L∙min-1 
PETCO2, mmHg 
MCAv, cm∙s-1 
 12.68 ± 4.76 
44.35 ± 3.42 
70.83 ± 7.87b 
16.86 ± 2.47 
43.69 ± 2.46 
46.42 +5.96 
17.74 ± 4.04 
43.43 ± 2.07 
45.96 ± 5.53 
21.13 ± 8.38a 
41.21 ± 3.71 
46.07 ± 7.33 
Values are expressed as means ± SD. aSignificantly different from baseline (p < 0.05). bSignificantly different from all other measurement periods (p < 0.05).  
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5.3 Cognitive Responses 
5.3.1 OTS-4 Accuracy 
FCS-4 (Table 3) showed no significant main effects for time (p = 0.151) or 
condition (p = 0.921) and displayed no significant interaction (p = 0.974). 
MCC-4 (Table 3) showed no significant interaction effect (p = 0.891), or any 
significant main effects for time (p = 0.055) or condition (p = 0.525). 
5.3.2 OTS-4 Response Time  
FCL-4 (Table 3) showed a significant main effect for time (p = 0.028); however, 
there was no significant main effect for condition (p = 0.656) or interaction effect (p = 
0.612). Overall post hoc analysis showed that FCL-4 was significantly faster at T-LIM 
(5792.54 ± 1697.53 ms) than at baseline (7721.50 ± 2474.33 ms, p = 0.41) and post-wash 
in (7009.45 ± 1939.26 ms, p= 0.46). Specifically, FCL-4 was only significantly different 
in the Poikilo condition between baseline (7005.44 ± 2994.79) and T-LIM (4065.09 ± 
1251.79, p = 0.026).  
There was a significant main effect for time (p = 0.004) when looking at MLC-4 
(Table 3); however, there was no significant main effect for condition (p = 0.588) or 
significant interaction (p = 0.481). Overall post hoc analysis showed that MLC-4 was 
only significantly different at T-LIM (6916.44 ± 2449.99 ms) when compared to baseline 
(9656.03 ± 3538.33 ms, p = 0.003). Specifically, MLC-4 was only significantly different 
in the Poikilo condition between baseline (8588.06 ± 3676.74) and T-LIM (4376.22 ± 
1182.70, p = 0.040). 
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Table 3. One-touch stockings of Cambridge performance (4 moves).  
  Baseline Post Wash-in IHE T-LIM 
Poikilocapnia      
Problems solved on 1st choice 
Choices to correct answer 
Latency to 1st choice (ms) 
Latency to correct answer (ms) 
 3.13 ± 0.99 
1.34 ± 0.38 
7005.44 ± 2994.79 
8588.06 ± 3676.74 
3.5 ± 0.76 
1.13 ± 0.19 
6559.09 ± 3702.22 
7458.94 ± 5155.44 
3.25 ± 1.16 
1.22 ± 0.31 
7735.00 ± 6506.71 
8588.53 ± 6780.02 
3.5 ± 0.76 
1.22 ± 0.25 
4065.09 ± 1251.79a 
4376.22 ± 1182.70a 
Isocapnia      
Problems solved on 1st choice 
Choices to correct answer 
Latency to 1st choice (ms) 
Latency to correct answer (ms) 
 3.13 ± 0.99 
1.34 ± 0.42 
8414.72 ± 4114.35 
10100.59 ± 4603.94 
3.5 ± 0.93 
1.16 ± 0.30 
7112.50 ± 3389.46 
7402.31 ± 3172.10 
3.25 ± 0.71 
1.28 ± 0.34 
7880.78 ± 3956.93 
9144.03 ± 5731.15 
3.13 ± 0.83 
1.41 ± 0.38 
6545.03 ± 2926.15 
8036.25 ± 4675.45 
Indomethacin      
Problems solved on 1st choice 
Choices to correct answer 
Latency to 1st choice (ms) 
Latency to correct answer (ms) 
 3.13 ± 0.99 
1.31 ± 0.35 
7744.34 ± 3003.44 
10279.44 ± 7193.89 
3.5 ± 0.53 
1.19 ± 0.22 
7356.75 ± 2556.44 
7899.63 ± 2767.68 
3.25 ± 0.89 
1.28 ± 0.39 
7222.47 ± 4372.61 
8356.50 ± 5361.63 
3.25 ± 0.89 
1.41 ± 0.40 
6767.50 ± 3672.14 
8336.84 ± 6276.03 
Values are expressed as means ± SD. aSignificantly different from baseline (p < 0.05). No significant differences were observed between conditions within each 
measurement period.  
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5.3.3 OTS-6 Accuracy 
There was no significant main effects for condition or significant interaction effect 
when examining FCS-6 (Table 4); however, there was a significant main effect for time 
(p = 0.039). Upon further examination of post hoc analysis, there were no significant 
differences between any time points. 
MCC-6 (Table 4) had no significant interaction effect (p = 0.725) or main effect for 
condition (p = 0.284); however, there was a significant main effect for time (p = 0.003). 
Pairwise comparisons showed that MCC-6 was only significantly different between 
baseline (1.59 ± 0.38) and IHE (1.24 ± 0.22, p = 0.045). 
5.3.4 OTS-6 Response Time 
FCL-6 (Table 4) did not have a significant main effect for time (p = 0.068) or 
condition (p = 0.52); nor did it show any significant interaction effect (p = 0.307). 
MLC-6 (Table 4) had a significant main effect for time (p = 0.044), but not for 
condition (p = 0.596). Furthermore, MLC-6 did not show a significant interaction effect 
(p = 0.544). However, despite MLC-6 being noticeably faster at T-LIM, further post hoc 
analysis did not show any significant differences between any time points. 
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Table 4. One-touch stockings of Cambridge performance (6 moves). 
  Baseline Post Wash-in IHE T-LIM 
Poikilocapnia      
Problems solved on 1st choice 
Choices to correct answer 
Latency to 1st choice (ms) 
Latency to correct answer (ms) 
 2.38 ± 1.30 
1.47 ± 0.36 
23337.50 ± 17136.64 
25450.79 ± 21276.05 
3.75 ± 0.46 
1.06 ± 0.12 
20461.22 ± 11111.75 
17848.43 ± 9254.01 
3.63 ± 0.74 
1.09 ± 0.19 
16383.91 ± 9804.42 
15449.91 ± 9720.79 
3.00 ± 1.31 
1.31 ± 0.44 
13982.38 ± 11593.44 
15154.37 ± 12866.25 
Isocapnia      
Problems solved on 1st choice 
Choices to correct answer 
Latency to 1st choice (ms) 
Latency to correct answer (ms) 
 2.50 ± 1.20 
1.69 ± 0.86 
31702.75 ± 32471.95 
34668.09 ± 31522.13 
2.25 ± 1.49 
1.53 ± 0.53 
26264.06 ± 21670.86 
28608.28 ± 21441.30 
3.00 ± 1.07 
1.34 ± 0.33 
19439.59 ± 11322.71 
21763.34 ± 13288.04 
2.50 ± 1.41 
1.44 ± 0.46 
13644.16 ± 8299.46 
15967.34 ± 8791.23 
Indomethacin      
Problems solved on 1st choice 
Choices to correct answer 
Latency to 1st choice (ms) 
Latency to correct answer (ms) 
 2.63 ± 0.92 
1.63 ± 0.58 
19981.65 ± 13326.08 
30463.97 ± 31795. 75 
3.25 ± 1.04 
1.22 ± 0.31 
17643.62 ± 12387.67 
23245.50 ± 24360.28 
2.88 ± 1.36 
1.28 ± 0.34 
22541.80 ± 14737.88 
25861.28 ± 20207.48 
2.63 ± 0.74 
1.31 ± 0.26 
11810.35 ± 7171.53 
16357.75 ± 12204.41 
Values are expressed as means ± SD. No specific significant differences were observed between conditions or measurement periods. Only overall significant 
differences were observed between measurement periods as discussed in text. 
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6 Discussion 
The purpose of the present study was to examine cognitive performance of 
individuals completing an executive functioning task during passive heat stress with and 
without concomitant changes in CBF. This was accomplished through the combination of 
a pharmacological intervention (indomethacin) and dynamic end-tidal forcing to achieve 
the desired physiological manipulations. Based on previous psychophysiological 
research, it was hypothesized that both accuracy and response time indices of complex 
cognitive performance (OTS-6) would be diminished with IHE ( ?̅?𝑠𝑘  ≥ +3°C above 
baseline, n/c in Tre) as well as upon attainment of T-LIM (Tre ~1.5°C above baseline). 
Furthermore, it was hypothesized that OTS-6 would be affected by a reduction in CBF 
through hyperventilation-induced hypocapnia (due to hyperthermia) or via the 
pharmacological intervention (indomethacin). The main findings of this study are; 1) 
simple and complex OTS performance was unaffected by heat stress as well as reductions 
in CBF and PETCO2 and, 2) improvements in OTS response time were associated with 
intensifying heat stress. These data suggest that, independent of thermal changes during 
passive heat stress, reduced CBF does not impair cognitive performance, specifically 
executive functioning.  
6.1 Cognitive Performance and Heat Stress 
A central finding of this thesis was that neither OTS-4 nor OTS-6 was affected with 
increasing passive heat stress. This lack of change in cognitive performance occurred 
despite significant increases in ?̅?𝑠𝑘, Tre, TC and TS from baseline/post wash-in levels to 
IHE and T-LIM. Measures of OTS accuracy (FCS/MCC) were relatively unchanged with 
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heat stress regardless of task complexity, with only MCC-6 being significantly different 
between post wash-in and IHE. OTS response time indices (FCL/MLC) were unchanged 
during OTS-6; however, overall OTS-4 response time markedly improved at T-LIM 
compared to baseline, post wash-in and IHE.  
Consistent with these findings, previous research (Schlader et al., 2015) has shown 
that passive heat stress (Tre = +1.0-1.6°C) has a similar effect on OTS performance. 
Specifically, Schlader et al. (2015) found that, in younger adults, OTS response time 
improved while measures of accuracy remained unchanged. However, other studies 
(Gaoua et al., 2011; Gaoua et al., 2012) have found that passive heat stress inducing 
changes in ?̅?𝑠𝑘 , increases in Tre, or both, resulted in diminished OTS performance. 
Furthermore, previous research (Gaoua et al., 2011; Gaoua et al., 2012) examining OTS 
performance during severe passive heat stress has also suggested that higher feelings of 
displeasure as a result of rapid increases in ?̅?𝑠𝑘 cause reduced cognitive performance; 
however, the present data fail to support this observation. However, despite increasing 
?̅?𝑠𝑘, TS and TC (by 3.94 ± 0.32°C, 1.2 ± 0.3 and 0.6 ± 0.5, respectively) upon IHE (< 5 
min of heat exposure) in the current study, accuracy and response time indices were 
relatively unchanged compared to values at post wash-in across all conditions. These 
contradictory and inconsistent results may be due, in part, to the heat stress protocol 
utilized. Similar to Schlader et al. (2015), the current study used water-perfusion suits 
(LCG) to induce passive heating as opposed to an overall environmental heat exposure as 
seen in other previous research (Gaoua et al., 2011; Gaoua et al., 2012). Schlader et al. 
(2015) reported that the contradictory results stem from the LCGs ability to tightly 
control temperature changes such that ?̅?𝑠𝑘 was maintained in their study during periods of 
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cognitive testing. This was opposite to that conducted in the Gaoua et al. papers (2011; 
2012), where there was marked variation in ?̅?𝑠𝑘 due to the inability of an environmental 
chamber to precisely regulate thermal manipulations within the body. In the current 
study, there was no down-regulation of LCG flow during periods of cognitive testing; 
therefore, unlike Schlader et al. (2015), the OTS test was not performed during periods of 
stable ?̅?𝑠𝑘. However, despite this there were no significant changes in OTS outcomes 
measures.  
Previous research (Gaoua et al., 2011; Gaoua et al., 2012; Hocking et al., 2001) has 
suggested that reductions in cognitive performance during heat stress stem from a 
competition for neuronal resources. However, the current data call into question previous 
assertions (Gaoua et al., 2011; Gaoua et al., 2012) regarding the effect of thermally-
mediated changes complex cognitive tasks in cognitive function. Furthermore, the current 
results suggest that the brain’s overall supply and ability to distribute these resources may 
not be as limited as previously thought. It appears that both simple and complex 
executive functioning tasks can be adequately completed despite dynamic instability 
within the body’s thermal equilibrium. Previous research has also proposed (Gaoua et al., 
2011; Gaoua et al., 2012) that cognitive performance decrements upon immediate 
exposure to heat stress may be due to the alliesthesial effect. This causes added 
attentional demands on a limited cognitive resource pool that is concurrently attempting 
to compensate for the sudden change in ?̅?𝑠𝑘. However, the results show that despite 
dynamic increases in ?̅?𝑠𝑘, and subsequently, higher feelings of displeasure (indicated by 
TC and TS) there were no changes in cognitive performance. This suggests that 
alterations in ?̅?𝑠𝑘 causing feelings of displeasure did not appear to draw a substantial 
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amount of neuronal resources from the existing supply pool. As such, dynamic ?̅?𝑠𝑘 
changes may not play as significant of role in executive functioning tasks as previously 
thought (Gaoua et al., 2011; Gaoua et al., 2012).  
The current data did reveal that there is a general trend towards improved OTS 
response time with increasing passive heat stress. It has been previously suggested 
(Gaoua et al., 2012) that this trend is likely to be a result of either an increase in nerve 
conduction velocity (Racinais et al., 2008) or an increase in impulsivity (Gaoua et al., 
2011).  The current findings suggest that this improvement in OTS response time is likely 
a result of both hypotheses. It has been previously shown (De Jesus et al., 1973; Johnson 
& Olsen, 1960; Lowitzsch et al., 1977) that nerve conduction velocity increases ~5% per 
°C change across a temperature range of 29-38°C (Kiernan et al., 2001). As such, it is 
possible that over the course of passive heating, conduction velocity could have increased 
upwards of ~30-40%. Since there were no significant changes in OTS accuracy measures 
in the current study, it is likely that participants did not become more impulsive with 
increasing heat stress. Rather, based on this lack of change in OTS accuracy indices, it is 
possible that participants simply benefitted from an increase in nerve conduction velocity 
that allowed them to select an answer more rapidly.  
Ultimately, the current data suggest that heat stress coupled with concurrent 
executive functioning tasks may not be detrimental to the brain’s ability to adequately 
distribute neuronal resources, as such it is possible to complete simple and complex tasks 
without much of a degradation in performance. 
6.2 Cognitive Performance and CBF 
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A novel finding of the current study is that reductions in CBF are not associated 
with significant changes in cognitive performance. Despite significantly reducing CBF in 
the Indo trial at post wash-in (-26.99 cm·s-1/~36.77% and -23.46 cm·s-1/~33.57% when 
compared to Poikilo and Iso, respectively), OTS-4 and OTS-6 accuracy and response 
time was relatively unaffected (Table 3 and 4). Furthermore, a reduction in CBF with 
concurrent passive heat stress did not result in altered cognitive performance at either 
IHE or T-LIM. This suggests that, irrespective of changes in thermal indices (?̅?𝑠𝑘, Tre, 
TC, TS), a reduction in CBF does not affect cognitive performance of an executive 
functioning task. These results further previous research (Schlader et al., 2013), which 
found no change in performance of a working memory task (nBack) despite a reduction 
in MCAv. Contrary to previous research (Schlader et al., 2013), the current study utilized 
a pharmacological intervention to significantly reduce baseline CBF below what was seen 
in Schlader et al. (2013). However, despite inducing a greater magnitude of CBF 
reduction in the current study, it did not elicit any further reduction in cognitive 
performance. 
The rationale behind the lack of changes observed during periods of reduced CBF 
are likely two-fold. Firstly, although indomethacin significantly reduced CBF, it is 
possible that the overall 𝐶𝐷𝑂2 was not significantly reduced due to the brain’s ability to 
increase O2 extraction when there is a reduction in overall blood flow. As previously 
discussed, the brain has the ability to up-regulate O2 extraction to match necessary 
demands up to a ~40-50% reduction in CBF (Bain et al., 2014). Secondly, similar to 
Schlader et al. (2013), who concluded that the lack of change in cognitive performance 
was due to the cognitive test used, the current study’s results are primarily attributed to a 
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learning effect with the OTS task. Despite randomizing trial order, the Indo trial was 
conducted last for some participants. Therefore, because the OTS test was performed 
multiple times within each trial, it is highly likely that participants acquired a learning 
curve by the third experimental session.  
A secondary novel finding of the current study is that PETCO2 does not appear to be 
a contributory factor regarding any observed changes in cognitive performance during 
passive heat stress. Despite adequately preserving PETCO2 at T-LIM in the Iso trial (42.75 
± 4.13 mmHg) vs. Poikilo trial (36.73 ± 3.59 mmHg) via end-tidal forcing, there was no 
significant difference in OTS accuracy or response time indices between the conditions. It 
is likely that despite inducing moderate hypocapnia during Poikilo, and a subsequent 
increase in Ve (17.59 ± 6.51 vs. 13.62 ± 3.87 L∙min-1 for T-LIM and Baseline, 
respectively), this stressor was not enough to invoke the necessary overload demands on 
attentional resource recruitment.  
The current findings have helped elucidate the possible effects that changes within 
the cerebrovasculature have on cognitive function. As with thermally-mediated effects, 
the proposed hypothesis was that a reduction in CBF and PETCO2 may impair the ability 
to recruit additional neuronal resources such that a concurrent cognitive task cannot be 
completed as effectively. However, the results indicate that cognitive function is 
remarkably well preserved in spite of dynamic manipulation of cerebrovascular variables. 
It is likely that the manipulations of CBF and PETCO2 were not the appropriate variables 
to induce sufficient neuronal resource demands. As previously discussed, it is probable 
that 𝐶𝐷𝑂2, the end product of CBF and 𝐶𝑎𝑂2, is more likely to have a significant effect on 
cognitive function. To this end, it may be necessary to manipulate both CBF and 𝐶𝑎𝑂2 
  58 
concurrently (e.g. combination of indomethacin and hypoxic exposure) such that a 
reduction in 𝐶𝐷𝑂2  can be ensured. Regardless, it can be concluded that CBF and PETCO2 
may not play an integral role in the preservation of cognitive function; however, it is 
more likely to be a function of 𝐶𝐷𝑂2 . As a result of the brain’s multiple protective 
mechanisms, the current data suggest that the brain is able to adequately sustain normal 
function when challenged with alterations in cerebrovascular homeostasis. To this end, it 
appears that the brain is much more adaptable in terms of utilizing neuronal resources 
during cerebrovascular changes. This is opposite to that observed during thermally-
induced variations within the body, which tend to invoke a heavier demand on these 
neuronal resource supplies. 
6.3 Technological Considerations/Limitations 
The present study used TCD flowmetry to assess CBF as measured by changes in 
MCAv; however, this relationship is only valid under the assumption that MCA vessel 
diameter remains constant. MCA vessel diameter has been shown to be unaffected by 
increases in ventilation (Valdueza et al., 1997) and across PETCO2 ranges of ± 25mmHg 
from baseline (Serrador et al., 2000; Willie et al., 2012). Furthermore, TCD 
measurements of MCAv have also been validated with prostaglandin inhibition during 
100mg oral dose of indomethacin (Xie et al., 2006). Due to the MCA supplying ~80% of 
CBF to each hemisphere, it is a useful indicator of global CBF; however, due to a lack of 
precision regarding regional changes it is unknown whether or not there were notable 
increases in local CBF with subsequent cognitive activation. 
The current study was also limited to measurements of PETCO2 as an estimation of 
PaCO2 levels. However, previous research (Brothers et al., 2011) has demonstrated that 
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PETCO2 accurately reflects changes in PaCO2. Therefore, the measured values of PETCO2 
in the current study accurately represent values of PaCO2 and observed hypocapnia 
accompanying prolonged heat stress. 
A final consideration with regards to the current study is the repeatability of the 
cognitive test. The OTS test has been previously used to successfully assess executive 
function during passive heat stress (Gaoua et al., 2011; Gaoua et al., 2012; Schlader et al., 
2015). Despite Cambridge Cognition software having multiple variations of the OTS 
task, in order to remain consistent within participants and between conditions, only one 
version was selected. Unfortunately, the OTS battery utilized does not randomize; 
therefore, the identical problem set is presented in the same order for every test. With 
subjects performing the OTS test twelve times over three experimental trials, it is very 
likely that they experienced a task learning effect. As such, the current results of the OTS 
task may not accurately represent the changes in cognitive performance that may occur 
during severe passive heat stress with and without concomitant changes in CBF. 
6.4 Perspective and Future Directions 
The current study is novel with respect to the methodological techniques used to 
manipulate specific variables. It is the first study to adequately separate the potential 
effect of CBF on executive function during passive heat stress through the use of 
indomethacin and end-tidal forcing. The use of indomethacin as a pharmacological 
intervention to selectively reduce CBF is a unique and effective method. Although severe 
passive heat stress has been shown to reduce CBF through hypocapnia-mediated 
vasoconstriction, it is likely that there are numerous confounding physiological factors 
that occur concurrently. Therefore, in order to specifically manipulate CBF, future 
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research into cognitive function should consider the use of indomethacin when attempting 
to examine CBF as a potential contributory mechanism.  
To further current conclusions, future research should employ more in-depth 
physiological measurement techniques (e.g. near-infrared spectroscopy - NIRS) to 
achieve a better understanding of the changes occurring with similar experimental 
conditions. By implementing techniques such as NIRS, researchers are able to examine 
the actual effect on 𝐶𝐷𝑂2, which is likely to be a primary contributing factor. Although 
assessing MCAv gives a general idea of the global CBF changes in the 
cerebrovasculature, we are not able to determine what, if any, fluctuations are occurring 
with 𝐶𝐷𝑂2. As previously discussed, it may be necessary for future research to include an 
experimental condition in which indomethacin is administered concomitantly with either 
hypoxia exposure or during a poikilocapnic heat stress trial in order to truly elicit a 
reduction in 𝐶𝐷𝑂2. 
Future research should also ensure that the cognitive task(s) is sufficient to cause a 
neuronal overload in order to elicit potential performance changes. Furthermore, a varied 
battery of cognitive tasks should be employed in order to distinguish if any other 
cognitive processes are affected by changes in the cerebrovasculature during passive heat 
stress. 
It is also important to note that the current findings of this thesis can only pertain to 
changes PETCO2 and CBF during situations of prolonged passive heat stress. 
Additionally, it is unlikely, that during prolonged heat stress in typical conditions 
(poikilocapnia), to observe the preservation of PETCO2 achieved via end-tidal forcing or 
the reduction in CBF achieved via indomethacin. However, it is important to note that the 
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current thesis was strictly looking at the potential mechanisms behind observed changes 
in cognitive performance.  
6.5 Conclusions 
The purpose of the present study was to examine the effect of CBF and PETCO2 on 
cognitive function during incremental levels of passive heat stress. It was demonstrated 
that cognitive performance (OTS accuracy and response time) remained relatively 
unchanged irrespective of changes in CBF via pharmacological intervention (Indo) or 
preservation of PETCO2 via end-tidal forcing. In contrast, improvement of OTS response 
time was associated with increasing intensity of passive heat stress; however, OTS 
accuracy indices did not significantly change as a result of increases in either ?̅?𝑠𝑘, Tre, or 
both, despite inducing hyperthermia corresponding to +1.5°C above baseline Tre. 
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Appendix A: One-Touch Stockings of Cambridge 
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OTS Description:  
OTS is a spatial planning test variant based upon the CANTAB Stockings of Cambridge 
test. 
This test gives a measure of frontal lobe function. 
Display 
 
Figure. X The OTS training screen showing a 1-move problem. 
The subject is shown two displays containing three coloured balls. The displays are 
presented in such a way that they can easily be perceived as stacks of coloured balls held 
in stockings or socks suspended from a beam. This arrangement makes the 3-D concepts 
involved apparent to the subject, and fits with the verbal instructions. There is a row of 
boxes containing numbers at the bottom of the screen, from one upwards. 
Task 
The test administrator first demonstrates to the subject how to use the balls in the lower 
display to copy the pattern shown in the upper display. The balls may be moved one at a 
time by touching the required ball, then touching the position to which it should be 
moved. 
The subject is shown one demonstration problems, then must solve three further 
problems. These problems increase in complexity, from one move to four moves. If the 
subject makes too many moves in attempting to solve these problems, the computer 
presents the ideal solution to the subject (Figure. X).  
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Figure. X OTS training phase after solving the first example problem 
Next the subject is shown more problems, and must work out how many moves the 
solutions require in their head, then touch the appropriate box at the bottom of the screen 
to indicate the number of moves required (Figure. X). 
 
Figure. X OTS assessed phase showing a 5-move problem. 
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OTS test modes: 
The OTS test has five modes: 
 5-choice-legacy-20 
 6-choice-20 
 6-choice-legacy-24 
 7-choice-15 
 7-choice-24 
For each of these modes, the first number (5, 6 or 7) refers to the number of boxes along 
the bottom edge of the screen, and the second number (15, 20 or 24) refers to the number 
of assessed problems that the subject must solve. 
For the 6-choice-20 mode, the 7-choice-15 mode and the 7-choice-24 mode, the 
maximum number of moves required to solve the most difficult problems in these modes 
is one fewer than the number of boxes along the bottom of the screen. Unless you have 
previously tested participants using these modes, we recommend that you should use the 
6-choice-20, 7-choice-24 and 7-choice-15 modes only (depending on your study 
population). 
Administration time 
This test takes around eight to twelve minutes to administer. 
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Appendix B: Environmental Ergonomics Laboratory 
Screening Form 
Environmental Ergonomics Laboratory Screening Form 
 
Please read over the questions below*. They are to assist in assessing whether you are fit 
to participate in this study. Please ask the investigators if you have any queries before you 
begin filling out the form. 
 
 
1. Has your doctor ever said that you have a heart and/or cardiovascular 
condition (congestive heart failure, hypertension, sickle-cell anemia 
etc.) and that you should only do physical activity recommended by a 
doctor? YES     NO 
2. Do you feel pain in your chest when you do physical activity? YES     NO 
3. In the past month, have you had chest pain when you were not doing 
physical activity? YES     NO 
4. Do you lose your balance because of dizziness or do you ever lose 
consciousness? YES     NO 
5. Do you have a bone or joint problem (for example, back, knee or hip) 
that could be made worse by a change in your physical activity? YES     NO 
6. Is your doctor currently prescribing drugs (for example, water pills) 
for your blood pressure or heart condition? YES     NO 
7. Do you know of any other reason why you should not do physical 
activity? YES     NO 
8. Do you have epilepsy or have you ever had a convulsion or a seizure? YES     NO 
9. Have you ever had severe (i.e., followed by loss of consciousness) 
head trauma?  YES     NO 
10. Do you have any hearing problems or ringing in your ears? YES     NO 
11. Are you pregnant or is there any chance that you might be? YES     NO 
12. Do you have metal in the brain/skull (except titanium)? (e.g., splinters, 
fragments, clips, etc.) YES     NO 
13. Do you have cochlear implants? YES     NO 
14. Do you have an implanted neurostimulator? (e.g., DBS, 
epidural/subdural, VNS) YES     NO 
15. Do you have a cardiac pacemaker or intracardiac lines or metal in your 
body? YES     NO 
16. Do you have a medication infusion device?  YES     NO 
17. Did you ever have a surgical procedure(s) to your spinal cord?  YES     NO 
18. Do you have any spine or heart abnormalities? YES     NO 
19. Do you have any gastrointestinal issues (such as peptic ulcers, GI tract 
bleeding)?  YES     NO 
20. Do you have any neuromuscular (e.g., epilepsy, Multiple Sclerosis, 
Cerebral Palsy) or skeletal (e.g., inflammatory or degenerative 
arthritis) disorders? YES     NO 
21. Do you currently have any diagnosed respiratory disease including 
mild asthma that may not require medication?  YES     NO 
22. Do you have hemorrhoids? YES     NO 
23. Are you a smoker? YES     NO 
24. Do you regularly consume excessive alcohol (i.e., on average more 
than 3 alcoholic beverages a day)? YES     NO 
25. Are you a regular user of NSAIDs (such as ibuprofen, naproxen, 
celecoxib, etc.)? YES     NO 
26. Are you currently taking any medications? 
If “Yes”, please list: ___________________________________ 
YES     NO 
27. Do you any allergies (allergies to medications included)? 
If “Yes”, please list: ___________________________________ 
YES     NO 
28. Do you suffer from kidney disease? YES     NO 
29. Do you take Ginko herbal supplements?  YES     NO 
 
Participant Name:  
 
  
Participant Signature:  
 
Date:  
 
    
Principal Investigator 
Signature: 
 
(Dr. Stephen Cheung, PhD) 
Date:  
 
Study Physician Signature:  
(Dr. Matt Greenway, MD, PhD) 
Date:  
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Appendix C: Informed Consent Form 
 
Informed Consent 
 
Date: 
Project Title: The influence of cerebral blood flow and PETCO2 on neuromuscular 
function during passive heat stress (EEL 073-3) 
Principal Investigator: Dr. Stephen Cheung, Ph.D. (Professor) 
Department of Kinesiology, Brock University, (905) 688-5550 x 5662, 
scheung@brocku.ca 
 
Principal Student Investigator: Mr. Geoff Hartley (Ph.D. Candidate) 
Faculty of Applied Health Sciences, Brock University, (905) 688-5550 x 4901, 
geoff.hartley@brocku.ca 
 
Co-Investigator: Dr. Matt Greenway, MD, Ph.D. (Adjunct Professor) 
Department of Kinesiology, Brock University, greenwam@mcmaster.ca 
 
INVITATION 
You are invited to participate in a study that involves research. The purpose of 
this study is to examine the separate and combined changes in cerebral blood flow (CBF) 
and cerebral alkalosis (increased pH) on the ability of your muscles to produce force 
(neuromuscular function) with high body temperature (hyperthermia). 
You may participate in this study if you are a male, 18-45 years of age, with no 
history of fainting, seizures or convulsions, and respiratory, cardiovascular, 
neuromuscular or kidney disease. You should not participate in this research if you are a 
smoker or have allergies to non-steroidal anti-inflammatory drugs (NSAIDS; such as 
advil/naproxen/celecoxib).  
WHAT’S INVOLVED 
There will be a total of four sessions. During the first session you will be 
screened for participation and given the opportunity to practice the experimental 
protocols. During the second, third and fourth sessions, blood flow to your brain will be 
reduced by either increasing your body temperature, your breathing rate, and/or drug 
manipulation. Prior to each session, you will be asked to refrain from alcohol and/or 
heavy exercise for 24 hours prior to the trial and caffeine on the day of the trial. 
Health Screening 
Before being allowed to participate, you will be asked to fill out a standard 
screening questionnaire detailing your current health status, use of medications and 
history of lung, heart, muscle and/or kidney disease. This will be done with Dr. Matthew 
Greenway, MD, Ph.D. 
Screening Session 
In the first session you will be introduced to all of the equipment being used 
during the experimental sessions. The protocols for each session will be explained in 
detail and any questions regarding the study will be answered. Subsequently, you will 
have your height, weight, and the amount of body fat measured. Body fat testing will be 
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performed using skinfold calipers, which might cause a slight pinching sensation, and 
will be taken by someone of the same sex in a private room. 
During this session you will be asked to lay down quietly while blood flow 
through your internal carotid artery (located in your neck) is measured using Doppler 
ultrasound. Similarly, blood flow velocity through your middle cerebral artery (located 
within your skull) will be measured. Previous research has found that only 70% of 
individuals have blood vessels that can be imaged using Doppler ultrasound and 
therefore, you may be excluded from the study if viable measurements are not obtainable. 
The time commitment for the familiarization session will be approximately 90 
min. 
 
Experimental Sessions 
There will be a total of three experimental sessions, administered in a random 
order, with the following protocol: 
 
Instrumentation 
During all sessions you will be required to dress only in a pair of your own shorts. 
You will have your internal temperature measured by wearing a rectal temperature 
sensor. The rectal sensor consists of a very thin and flexible plastic tube that you insert 15 
cm beyond the anus. Before and after each session you will have your body weight 
measured and provide a small urine sample, which we will use to measure your hydration 
status. A euhydration threshold of 1.02 will be used as a cut off value. If you are above 
this threshold, we will ask you to consume 0.5 L of water and we will reassess your 
hydration status 30 min later. If you are below the defined threshold at this point, we will 
continue with the study. If not, we will ask you to reschedule the session for a later date 
to ensure your safety during the experiments. 
When adequate hydration is confirmed, you will be asked to put on a liquid 
conditioning garment (LCG), which is similar to a diving wet suit lined with flexible 
PVC tubing throughout. The garment consists of a pair of pants and a jacket, leaving the 
head, hands, and feet uncovered. During the experiments, hot (46°C) water will be run 
through the tubing to increase core temperature. Skin temperature sensors will be taped 
onto the body surface at the following sites: forehead, abdomen, forearm, hand, quads, 
shin and foot, which will be used to calculate mean skin temperature. 
A 3-lead electrocardiogram will monitor your heart rate. A total of three skin sites 
on your chest and abdomen will be shaved and swabbed with alcohol to remove any oils 
or dead skin cells, which may interfere with recordings. Subsequently, electrodes will be 
attached to these sites with adhesive disks. Your blood pressure will be measured 
throughout each experiment with a finger blood pressure cuff placed on your left hand. 
Similarly, the oxygen saturation of your blood will be measured with a pulse oximeter 
placed over an adjacent finger. You will wear a soft silicone facemask to collect expired 
gases for determining the concentration of oxygen and carbon dioxide. Every time you 
Instrumentation
(20 min)
Baseline 
Measurements
(30 min)
Recovery
(30 min)
Passive 
Heating
a) Uncontrolled CO2 + high core temperature + placebo
b) Controlled CO2 + high core temperature + placebo, or
c) Controlled CO2 + high core temperature + indomethacin (drug)
Experimental 
Measurements
(Tc ~ 38.5°C)
Drug/Placebo 
Wash-in
(90 min)
Experimental 
Measurements
(Tc ~ 39.5°C)
Passive 
Heating
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exhale, the air will pass through a gas analyzer to measure the concentration of expired 
oxygen and carbon dioxide from your lungs. A computer controlled system will then 
adjust the gas levels appropriately for your next breath. This system allows the 
investigators to keep oxygen delivery constant under normal or hypoxic conditions while 
either “clamping” carbon dioxide levels at your resting values (controlled) or allowing 
them to fluctuate naturally (uncontrolled) throughout the experiment. You will be 
permitted to briefly remove the mask and drink if you require fluid during the 
experimental protocol. Middle cerebral artery blood flow will be measured non-
invasively by a transcranial Doppler ultrasound probe placed next to your ear (temporal 
window) on either side of the head.  
Surface electromyography (EMG) will used to measure muscle activity in the 
flexor carpi radialis (FCR) muscle (located in your forearm). Initially, your skin surface 
will be shaved, lightly abraded and cleansed with alcohol. The motor point (the most 
electrically sensitive region) of the FCR will be identified by placing an electrode to the 
backside of the forearm and using a metal probe to gently stimulate the front side of the 
forearm (overtop the muscle belly of the FCR) until the point at which the largest 
response with the least amount of voltage is identified (i.e., the motor point). Two surface 
EMG electrodes will be placed on the skin surface, one overtop the motor point and the 
other on the tendon located in the palm of the hand. A similar ground electrode will be 
placed on the back of the hand. This apparatus will remain connected throughout the 
duration of the experiment. 
Baseline Measures 
In addition to the above measures, your internal carotid artery and brachial artery 
blood flow will be measured during the baseline measurement period. Internal carotid 
artery blood flow will be measured non-invasively using a high-resolution ultrasound 
machine. You will lie on your back with a slight side tilt of the neck away from the side 
being scanned. Measurements will be taken on the neck below the jaw line over the 
duration of 10 cardiac cycles (approximately 60 seconds). Similarly, brachial artery blood 
flow will be measured while you lie on your back with your forearm extended in a 
comfortable position. Blood flow measurements will be taken in the top 1/3 of the upper 
arm over the duration of 10 cardiac cycles (approximately 60 seconds).  
Following blood flow measures, you will perform the neuromuscular test battery. 
The neuromuscular test battery is comprised of the following four tests: 
Motor Evoked Potential Recruitment Curve. The motor evoked potential (MEP) 
recruitment curve represents the ability of the brain to activate muscles at different force 
levels. MEPs will be evoked using a magnetic coil placed over your scalp. When 
activated, the magnetic coil will cause a very brief muscle twitch in your forearm. To 
identify the area of stimulation, a tight lycra cap will be positioned over your head. Using 
high stimulus intensity, the coil will be systematically moved over your scalp to 
determine the optimal location for eliciting a maximal amplitude MEP. Once the optimal 
position of the coil is established, it will be marked on the cap to ensure a constant coil 
placement throughout the experiment. To determine the MEP recruitment curve, 
stimulator intensity will be increased incrementally from the smallest observable muscle 
twitch by 10% increments until a maximal muscle twitch is observed. 
H-Reflex. The H-Reflex is a measure of the sensitivity of your nerves that attach 
the spinal column to the muscle. Initially, a maximal muscle twitch will be elicited by 
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electrically stimulating the nerve in your forearm. Once the maximal twitch is 
established, the EMG activity following a 5% maximal muscle twitch will be measured. 
Maximal Voluntary Contraction. A maximal voluntary contraction (MVC) 
represents the highest amount of force that you can produce during a muscular 
contraction. During MVC testing, your right arm will be secured in a custom made device 
used to isolate force production in the wrist. You will be asked to produce a 5-second 
MVC and will be verbally encouraged to maintain maximal force production throughout 
the duration of the contraction. EMG activity and force production will be recorded 
throughout the duration of your MVC. During the contraction, a maximal MEP will be 
elicited using identical techniques as mentioned above (see Motor Evoked Potential 
Recruitment Curve) to assess the capacity of your muscle to produce force, independent 
of your brain. 
Sustained Maximal Voluntary Contraction: Using similar procedures as the MVC 
(see Maximal Voluntary Contraction), you will be asked to perform a sustained, 120-
second MVC. You will be verbally encouraged to maintain maximal force production 
throughout the duration of the contraction. EMG activity and force production will be 
recorded throughout the duration of the sustained MVC. During the contraction, a 
maximal MEP will be elicited using identical techniques as mentioned above (see Motor 
Evoked Potential Recruitment Curve) to assess the capacity of your muscle to produce 
force, independent of your brain.  
Following the neuromuscular test battery, you will then perform the One Touch 
Stockings of Cambridge cognitive test. During this test, you will be shown two displays 
each containing three coloured balls. There is a row of numbered boxes along the bottom 
of the screen. An investigator will demonstrate how the balls in the lower display can be 
moved to copy the pattern presented in the upper display. You must then complete three 
further problems and determine (without moving the balls) how many ball moves are 
required to duplicate the pattern, then touch the appropriate box at the bottom of the 
screen to indicate your response. 
Wash-in Period 
You will then perform the wash-in phase of the placebo (visits “a” and “b”) or the 
indomethacin (visit “c”). The wash-in period will last 90 minutes allowing sufficient time 
for the drug concentration to peak in the blood stream. During this time, you may de-
instrument and rest or work quietly in the lab. 
Experimental Measures and Recovery 
Following the wash-in period, you will be subjected to (a) uncontrolled CO2 + 
high core temperature, (b) uncontrolled CO2 + high core temperature or (c) uncontrolled 
CO2 + high core temperature + indomethacin (drug) condition. During each condition, 
your core temperature will be passively increased from baseline to 39.5°C or until 
thermal tolerance. Experimental measures (identical to baseline measures) will be 
conducted when your core temperature is ~38.5C (approximately half way through the 
passive heating protocol) and ~39.5C (or whenever you feel unbearably hot). Following 
the attainment of each core temperature target (38.5C or 39.5C), the LCG will be 
adjusted to maintain your core temperature for the duration of the experimental 
measurements. Once all the experimental measures have been collected, you will de-
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instrument and will be monitored for 30 minutes throughout recovery to ensure that you 
are symptom free from any possible side effects caused by the experimental protocol. 
POTENTIAL BENEFITS AND RISKS 
You will receive $100 for completion of the experiment, with payment prorated for 
partial completion. Your participation in this project will benefit society as you data will 
provide more information on the influence of changes in CBF and cerebral alkalosis on 
neuromuscular function that occur during environmental stress. This information is 
important to further our understanding of the central (relating to the central nervous 
system) mechanism involved in neuromuscular fatigue. Furthermore, results from this 
study may provide useful information for individuals who are subjected to hypoxia and 
hyperthermia, either in the workplace (such as military pilots and industrial workers) or 
because of pathology (such as chronic obstructive pulmonary disease). 
There may be risks associated with participation. There will be at least two 
investigators trained in First Aid and CPR present for each experiment. The investigators 
will contact you later in the day following each session to check on your health status. 
Depending on your health status, you may be asked to consult with a physician. 
Experimental sessions will be terminated if: 
1. Heart rate has risen above 95% of its maximum (220-age) for 3 min. 
2. Core temperature rises above 39.5 oC. 
3. Systolic blood pressure drops below 80 mmHg for more than 1 min. 
4. Dizziness or nausea precludes further experimentation. 
5. You decide, for any reason, to end the experiment. 
6. The investigators determine that the participant is unable/unfit to continue. 
Symptoms that may be experienced with hyperthermia include: discomfort, 
sweating, flushing and redness in the face and body, thirst, loss of fine motor 
coordination due to sweating, minor mental confusion, dizziness, nausea and a drop in 
blood pressure. Given the level of hyperthermia employed in the proposed studies (≤ 
39.5°C), it is unlikely that any serious symptoms would arise. In event of persistent 
symptoms, the heating protocol would be terminated immediately, followed by the 
circulation of cold water through the LCGs, allowing for the return to normothermic 
levels.  
On rare occasion, you may unable to tolerate electrical stimulation of the nerve. 
Although this stimulation is not painful, the nervous system may perceive it, however 
brief, as harmful. As a result there is a potential for fainting. However, you will always be 
in a supine position during testing and therefore, the chance of injury will be remote. 
Furthermore, the use of skin fold calipers may cause a slight pinching sensation. All 
skin fold measurements will be taken in a private room by an investigator of the same 
sex. Adhesive tape used to secure instrumentation may cause slight skin irritation, 
although this adverse response is rare. Alternative adhesive options are available if 
needed.   
Additionally, alcohol and light abrasion used for prepping the skin for 
electrocardiogram and EMG recordings may leave the skin red and irritated. Moisturizer 
can be provided in such cases.  Razors used for shaving skin area prior to 
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electrocardiogram and EMG electrode placement may cause minor bleeding, although in 
the history of EMG use in the lab this has not occurred. If bleeding does occur, 
appropriate first aid will be administered. 
The finger cuff used for measuring blood pressure during the tests may induce 
some colouring at the distal end of the finger during measurements. This is not harmful to 
you and colouring will return within 1-2min after removing the cuff. Some people also 
report numbness of the finger with measurement durations exceeding 1-2hrs. Upon 
removal of the cuff, this feeling subsides within 1-2min. 
Indomethacin 
You should not ingest the indomethacin or placebo supplement if you have any 
dietary or religious restrictions to the consumption of animal byproducts as the capsule 
(for indomethacin and placebo) and contents of the placebo contain gelatin. The acute 
oral dose of indomethacin poses minimal risk to otherwise healthy humans. Common 
side effects include gastrointestinal distress, peptic ulcers, headache, dizziness and 
changes in kidney function; however, this is more typically associated with chronic 
dosage. You should not take indomethacin if you suffer from kidney disease. The 
incidence of other adverse reactions to indomethacin are very low (<10%) however may 
include myocardial infarction, stroke, high blood pressure, excessive fluid build-up in 
tissue, worsening of heart failure, drowsiness, tinnitus (ringing in the ears), rash, Stevens-
Johnson syndrome (skin condition), nausea, shortness of breath, diarrhoea, anorexia, 
flatulence, bleeding in the GI tract, prolonged bleeding time, anemia (decreased red blood 
cells), blood dyscrasias (abnormal blood composition), elevated liver enzymes, hepatitis, 
anaphylactic reactions, bronchospasm (inflammation of the airway), blurred vision, 
decreased kidney function, kidney failure, potassium build-up, bladder inflammation and 
reversible female infertility. Indomethacin should not be taken if you take ACE 
inhibitors, angiotensin II receptor blockers, beta-blockers, cholestyramine, 
corticosteroids, cyclosporine, CYP2C9 Inhibitors (fluconazole, voriconazole), digoxin, 
diuretics, drugs that increase the risk of bleeding (anticoagulants, anti-platet drugs, 
heapin), lithium, methotrexate, potassium supplements, or probenecid. You should not 
take indomethacin if you take the herbal supplement Ginkgo. 
To counteract any stomach issues (such as ulcers, acid reflux, nausea, etc.) caused 
by the indomethacin drug, you will be given a 150 mg antacid (such as Zantac). Although 
negative reactions to antacids are extremely rare, side effects include headache, general 
discomfort, dizziness, drowsiness, insomnia, vertigo, blurred vision, mental confusion, 
agitation, depression, and hallucinations, reversible involuntary movement disorders, low 
heart rate, high hear rate, irregular heart beats, constipation, diarrhea, nausea/vomiting, 
abdominal discomfort/pain, hepatitis, kidney disease, muscle and joint pain, blood count 
changes, rash, chest pain, bronchospasm, fever, anaphylaxis, edema, and low blood 
pressure. Zantac should not be taken if you take diazepam, lidocaine, phenytoin, 
propranolol and theophylline, triazolam, midazolam, ketoconazole, atazanavir, 
delaviridine, or gefitnib. Zantac may cause drowsiness therefore, you should take 
precaution when driving (etc.) following the trial). 
Rectal Probe 
  85 
When performed in a healthcare setting, insertion of the rectal probe is a controlled 
act as set out in the Regulated Health Professions Act. While this act does not extend to 
research outside of a healthcare setting, you should be aware of the following potential 
risks: 
 Insertion of the rectal probe can stimulate the vagus nerve, which can cause 
slowing of the heart rate, which may lead to fainting. This is more likely to 
happen if you have a low resting heart rate. 
 Perforation of the bowel can lead to peritonitis, a serious infection of the 
abdominal cavity. 
 You should not participate in this research if you are pregnant, are under the 
influence of alcohol or other sedating substances (tranquilizers, sleeping pills, 
street drugs) or have any history of fainting or heart disease. 
Rectal probes are classified as “single use only”; however, are commonly used 
multiple times by one individual without any issue. The rectal probe may become slightly 
discoloured during the sterilization process that occurs between lab visits. Therefore, you 
will be given a new rectal probe upon request or if an investigator believes that the 
integrity of the probe has been damaged in the sterilization process. 
Transcranial Magnetic Stimulation 
Although single pulse TMS is regarded as safe, the greatest acute risk is the 
occurrence of seizures and syncope (occurring in 1 of every 1000 studies). Other adverse 
effects of single pulse TMS include local discomfort at the site of stimulation, muscle 
soreness caused by muscle contraction, local heating and temporary hearing cause by the 
rapid deformation of the magnetic coils, headaches, dizziness, neck stiffness and pain. 
These risks are more prevalent in repetitive TMS, unlike the single pulse protocols 
employed in the proposed studies. 
CONFIDENTIALITY 
Access to this data will be restricted to Dr. Cheung and the principal student 
investigator, Mr. Geoff Hartley. Your participation will remain confidential. The data 
collected from this investigation will be kept secured on the premises of the Department 
of Kinesiology at Brock University in Dr. Cheung’s office or laboratory, and will not be 
accessed by anyone other than the listed investigators.  
Investigators will require disclosure of your name and contact information (phone, 
email), and therefore your participation is not anonymous during the conduct of the 
research. All participants will have their names removed from any data. The master list 
matching participants to data will be kept by Dr. Cheung and/or Mr. Hartley, and will be 
destroyed following the publication of data. 
All information you provide is considered confidential; your name will not be 
included or, in any other way, associated with the data collected in the study. 
Furthermore, because our interest is in the average responses of the entire group of 
participants, you will not be identified individually in any way in written reports of this 
research.  
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VOLUNTARY PARTICIPATION 
Participation in this study is voluntary. If you wish, you may decline to answer 
any questions or participate in any component of the study. Further, you may decide to 
withdraw from this study at any. Participation, non-participation, or withdrawal from the 
study will not affect your standing at Brock University. 
PUBLICATION OF RESULTS 
Results of this study may be published in professional journals and presented at 
conferences, but your personal information and participation will remain confidential. 
Approximately one month after we finish testing all participants, we will provide you 
with a summary of your own results and also the overall group results. Feedback about 
this study will be available from Dr. Stephen Cheung (stephen.cheung@brocku.ca, 905-
688-5550x5662). 
CONTACT INFORMATION AND ETHICS CLEARANCE 
If you have any questions about this study or require further information, please 
contact the Principal Investigator or the Faculty Supervisor (where applicable) using the 
contact information provided above. This study has been reviewed and received ethics 
clearance through the Research Ethics Board at Brock University (12-271). If you have 
any comments or concerns about your rights as a research participant, please contact the 
Research Ethics Office at (905) 688-5550 Ext. 3035, reb@brocku.ca.  
CONSENT FORM 
I agree to participate in this study described above. I have made this decision 
based on the information I have read in the Information-Consent Letter. I have had the 
opportunity to receive any additional details I wanted about the study and understand that 
I may ask questions in the future. I understand that I may withdraw this consent at any 
time. My participation, non-participation, or withdrawal from the study will not affect my 
standing at Brock University.  
Please note that Dr. Greenway is responsible only for your health screening and 
the prescription of Indomethacin (drug). All other experimental procedures are the 
responsibility of the Principal Investigator (Dr. Cheung).  
Participant Name:  
 
  
Participant Signature:  
 
Date
: 
 
 
Principal Investigator 
Signature: 
 
(Dr. Stephen Cheung, PhD) 
Date
: 
 
 
Study Physician Signature:  
(Dr. Matt Greenway, MD, 
PhD) 
Date
: 
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Thank you for your assistance in this project. Please keep a copy of this form for your 
records. 
